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ABSTRACT 
 
The effect of chirality was investigated on selected physico-chemical properties by designing, 
synthesizing and analysing a series of racemic multicomponent crystals and their chiral 
counterparts. Eleven new crystalline materials were synthesised by combining phenylsuccinic 
acid (racemate or the S-enantiomer), a dicarboxylic acid, with primary or aromatic amines 
(aniline, pyridine, 4-picoline, 2,4-lutidine, 3,4-lutidine and 3,5-lutidine) and a drug pyrazine 
carboxamide (PCA). The carboxylic acids were combined with the amines to ensure the 
formation of the multicomponent crystals via acid-base heterosynthons. The varied positions 
of the functional groups on the aromatic amines gave rise to fine tune the packing of the 
crystals. The multicomponent crystals formed were examined by differential scanning 
calorimetry, thermogravimetric analysis, powder and single crystal X-ray diffraction. Fourier 
transform infrared spectroscopy was also performed for the complete characterisation of the 
new compounds. Ten out of the eleven novel compounds afforded multicomponent crystals 
with the expected composition, i.e. both the acid and the base were included in the crystal. 
These crystallisations resulted in a variety of different crystal forms, such as a true salt ([(R,S)-
PSA-][ANI+]), a salt solvate ([(S)-PSA2-][2ANI+]·ANI), solvates ((R,S)-PSA·2PYR, (R,S)-
PSA·2(4PIC), (R,S)-PSA·2(2,4LUT), (R,S)-PSA·2(3,4LUT) and 2(S-PSA)·4(3,4LUT)), co-
crystal salts ([(R,S)-PSA2-]2[3,5LUT+]·2(R,S)-PSA and 2[(S)-PSA2-]4[3,5LUT+]·4 (S)-PSA) 
and a co-crystal (R,S)-PSA‧PCA. In these crystals, the phenylsuccinic acid showed great 
conformational variety. The analysis of the crystal packing (Z and related parameters, void 
analysis, etc.) highlighted the complexity of the packing of the multicomponent crystals and 
the significant differences between the racemic multicomponent crystals and their chiral 
counterparts. The acid-base heterosynthon, depicted as 𝑅2
2(7), was formed between the 
carboxylic acid and the pyridine moiety only in five of the multicomponent crystals. 
Interestingly, in the co-crystal of (R,S)-PSA‧PCA the carboxylic acid formed hydrogen bonds 
via the amide functional group of the PCA instead of via the nitrogen atom in the aromatic ring. 
The occurrence of the 𝑅2
2(7) synthon was investigated with the aid of the Cambridge Structural 
Database and the statistical analysis showed that the heterosynthon is formed only in 25-30% 
of the cases. It was also concluded that formation of the 𝑅2
2(7) synthon is less expected when 
crystallising enantiopure crystals because the limitations of the packing of chiral compounds 
adds an extra constraint to the packing of the crystal. 
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Introduction 
1.1 Supramolecular chemistry 
Nobel Laureate Jean-Marie Lehn described supramolecular chemistry as “the chemistry of 
molecular associations and of the intermolecular bond”.1 The need to comprehend the making 
of electrical activities through charged species of sodium and potassium in the body nerve 
system2 led to his research in the area of supramolecular chemistry. In 1806, the first 
multicomponent crystal, chlorine hydrate, was isolated by Humphrey Davy, but it was only 
later, in 1896 with Emil Fischer’s investigation on the functioning of enzymes that a specific 
approach in supramolecular chemistry truly began, and was further conducted by the study of 
Lehn on host-guest compounds.3  
Supramolecular chemistry developed at high rate during the last decade, shown by a large 
number of publications. Nowadays, it has progressed into an interdisciplinary field linking 
physics, biology and chemistry and its development had a significant impact on the synthesis 
of crystalline structures of distinctive forms and sizes with the required functions. These 
supramolecular compounds are formed by linking molecules via intermolecular interactions 
that are described by their capacity to contribute in directional or non-directional forces (Figure 
1.1). Although nondirectional interactions have a significant part to play in the spacing and 
conformation of supramolecular elements, directional forces usually are important for the 
geometry and spatial arrangement of component molecules.4,5,6 The general purpose of 
supramolecular chemistry, is the synthesis of supermolecules using hydrogen bonding, π-π 
stacking, charge transfer, Van der Waals and/or dipole-dipole interactions with desired 
properties or functions.7 
 
Figure 1.1 Schematic description of molecular and supramolecular chemistry. 
bonding, π-π stacking, Van der Waals, charge transfer and dipole-dipole interactions.7 
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1.2 Multicomponent crystals 
Multicomponent crystals (MCCs) have a minimum of two distinct chemical entities and can be 
categorised as co-crystals, salts, solvates or hydrates. The earliest multicomponent crystal 
reported in 1844 by Friedrich Wöhler was quinhydrone, a green solid resulting from mixing 
solutions of benzoquinone and hydroquinone, in a 1:1 ratio.8 Over the years co-crystals have 
been denoted and categorised as molecular complexes9, multicomponent molecular 
crystals10,11, and ionic co-crystals.12 In 2012, forty six authors13 issued a viewpoint article 
entitled, “Polymorphs, Salts, and Co-crystals: What’s in a name” defining the term co-crystal 
as “solid crystals made from at least two distinctive molecular and/or ionic compounds usually 
in a stoichiometric ratio”. The components present in crystals are all organic species but the 
presence of specific elements in the structure of these supermolecules, such as charged species, 
water, solvent and neutral species is used to distinguish the type of crystals but also to classify 
them as salt, hydrate, solvate or co-crystal, respectively. Another important occurrence in 
supramolecular architecture is polymorphism, which is the formation of different packing 
arrangements of the same compound (Figure 1.2).14 
 
Figure 1.2 Schematic representation of a salt, co-crystal, solvate, hydrate and polymorphs. 
The classification of crystal structures brought some disagreement between the Food and Drug 
Administration (FDA) and the academic community in order to find the most appropriate 
classification. Back in 2011, the FDA agency announced draft guidelines regarding the 
definition and classification of co-crystals as “dissociable API-excipient molecular 
 
 
                                               
                    Target                           Solvent/Water         Counter ion               Co-former                 
 
  Polymorph I      Polymorph II    Solvate/Hydrate              Salt                        Co-crystal              
Cofor er
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complexes”.15 In reference to the work of Aitipamula et al. contesting the FDA classification 
by suggesting the combination of co-crystals with salts, the classification of multicomponents 
crystals was re-examined. The authors claimed that co-crystals and salts cannot have different 
sets of rules and regulations since the differentiation of these crystals is at times challenging 
and coformers which are similarly behaving like ions, frequently behave more like APIs than 
like an inactive substance. However, the concept of Aitipamula et al. was further reviewed by 
Grothe et al16. For example, looking at the multicomponent crystal of isonicotinamide 
pyromellytic acid hydrate containing two ions and a solvent, the classification proposed by 
Aitipamula et al. does not provide a group for this kind of crystals. However, the Venn diagram 
proposed by Grothe et al. does provide a name, a salt solvate which requires the asymmetric 
unit to have a solvent molecule and either a coformer or a minimum of two ions (Figure 1.3). 
The incomplete categorisation of Aitipamula et al. led to a reconsideration of the three main 
classes, listed in Table 1.1, as well as their seven subclasses. By definition multicomponent 
crystals are crystals with a minimum of two distinctive residues in the crystal lattice. The 
amount of residues present in the asymmetric unit is represented by the symbol ZR and these 
elements can be of different kind, a solvent, a co-former or a charged species. The types of 
residues are important to determine the subclasses of crystals which is well described by the 
classification system recommended by Grothe et al. Originating from the Venn diagram, three 
main classes and seven subclasses are observed (Figure 1.3). 
 
 
 
Figure 1.3 Classification diagram of multicomponents crystal. 
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Table 1.1 Summary of the main and subclasses of multicomponent crystals.  
 
 
3 MAIN 
CLASSES 
SALT Crystal with a minimum of two ions 
CO-CRYSTAL Crystal containing a coformer molecule and either 
an extra coformer or a minimum of two ions 
SOLVATE Crystal containing a solvent molecule and either a 
coformer or a minimum of two ions 
 
 
 
 
 
7 SUBCLASSES 
TRUE SALT Only ions 
TRUE CO-CRYSTAL Only coformers 
TRUE SOLVATE At least one solvent and precisely one coformer, 
but no ions 
CO-CRYSTAL SALT At least one coformer and a minimum of two 
ions,  but no solvents 
CO-CRYSTAL 
SOLVATE 
At least one solvent and a minimum of two 
coformers,  but no ions 
SALT SOLVATE At least one solvent and a minimum of two ions, 
but no coformers 
CO-CRYSTAL SALT 
SOLVATE 
At least one solvent, and a minimum of two ions, 
with one or more coformers 
The concept of Aitipamula et al., that salt and co-crystals are alike in some circumstances to 
one another and to recommend that co-crystals and salts have to fall under the same group, is 
acceptable to the scientific community. Nevertheless, even though some crystals are very 
similar, others are very distinct due to the type of interactions present in salts (ionic) which can 
vary significantly from those in co-crystals.32  
 
1.3 Pharmaceutical co-crystals 
Pharmaceutical co-crystals are multicomponent crystals containing at least one active 
pharmaceutical ingredient (API) and one coformer compound, where the latter is typically 
selected from a list of chemicals generally regarded as safe (GRAS).17,18 These molecular 
constituents fuse through secondary interactions, typically hydrogen bonds, in a definite ratio 
in the lattice. The particular attention towards pharmaceutical co-crystals before and in present 
days is due to their possible usefulness as substitute drug elements with upgraded physico-
chemical properties. APIs frequently have unfavourable solid-state properties19, but these 
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properties can be changed by altering the solid state structure of the API with a coformer to 
improve its properties without compromising the therapeutic efficacy of the drug. However, 
the path to take to obtain a medicine is a major assignment and usually, developing a 
therapeutic co-crystal as the API into a medication may be separated to eight steps (see Figure 
1.4).20   
 
 
 
Figure 1.4 Drug development pathway for MCCs 
 
Through these manipulations medicines were improved. To date, only a few pharmaceutical 
multicomponent crystals have been approved by the FDA as medication. As an example the 
salt hydrate Entresto™, a product of Novartis for the treatment of chronic heart failure21, was 
approved in 2015. The salt hydrate is a mixture of sacubitril and valsartan with molecular 
formula C96H120N12Na6O21 (see Figure 1.5). Many other cases are under study such as 
metaxalone, the API present in Skelaxin®, prescribed for relief related to musculoskeletal 
soreness.22 The multicomponent crystals of metaxalone with succinic and fumaric acid known 
as GRAS compounds gave results with better bioavailability than metaxalone only.23 
 
 
Figure 1.5 Chemical structure of the salt hydrate Entresto™ 
Design 
& 
Co-former selection
Discovery Characterization Properties Pharmaco-
kinetics
Formulation
Process 
&
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1.4 Salt versus co-crystal formation 
If the constituents of the multicomponent crystals have ionizable functional groups such as 
carboxylic acid or amine moieties, it is possible to form a salt of the target compound by the 
displacement of the hydrogen atom from an acidic group to a basic moiety24. Co-crystals do 
not essentially display fixed stoichiometries but salts must exhibit fixed ratios due to their 
charged nature. A typical example to describe this problem occurs when carboxylic acids are 
co-crystallised with aromatic amines (Figure 1.6). In this case, the proton of the carboxylic acid 
can stay on the acid, forming a co-crystal, or occasionally, it transfers to the base to form a salt. 
The differentiation between these two extremes by X-ray diffraction methods locating the 
position of the hydrogen atom, can be challenging because of the low X-ray scattering power 
of the hydrogen.25 In some cases, the displacement of the proton might then be considered as a 
“continuum” from one extreme to the other.26 The geometrical analysis of the heavy atoms, i.e. 
the bond length of the C-O bonds, is often used to aid the decision on the question of co-crystal 
vs. salt formation. (Importantly, the observation of the X-ray analysis should be supported by 
spectroscopic measurements, typically Fourier Transform Infrared spectrometry.) 
 
                                 Co-crystal                                              Salt 
Figure 1.6 Differentiation of a co-crystal and a salt 
The outcome of the co-crystallisation of an acidic and a basic component, i.e. the formation of 
a salt or a co-crystal, is based on the pKa differences between the two parties. Nangia et al. 
defined the so called “pKa-rule” after investigating large amount of crystals obtained from co-
crystallisations of carboxylic acids and substituted pyridines as acid-base pairs.27 When 
calculating the ΔpKa values for each pairs of compounds crystallised together (ΔpKa = pKa 
(base) – pKa (acid))28 the following pattern was observed: compound pairs that resulted in 
negative ΔpKa values will most likely form co-crystals and when the difference is greater than 
2-3 pKa units, salt formation is expected. For a pKa difference in the range of 0 to 3, the 
outcome of the crystallisation is unpredictable. This rule of thumb was quantitated by Cruz 
Cabeza, who studied more than six thousand crystalline complexes with acid-base pairs 
obtained from the Cambridge Structural Datababse.29 Three areas were delimited and examined 
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individually due to their distinct occurrences. When the ΔpKa < -1 (defined as zone 1) it is 
almost certain to obtain a co-crystal; if the ΔpKa > 4 (zone 3) nearly all compounds formed are 
salts. When the ΔpKa value is between -1 and 4 (zone 2) both a co-crystal or a salt can be 
formed. It is also essential to note that pKa values may be influenced and are subject to change 
in various solvents, therefore the selection of a solvent is crucial, especially in syntheses of 
organic salts.30, 31 
 
1.5 Supramolecular synthons 
Multicomponent crystal design is based on the use of supramolecular synthons where the latter 
is defined as a linear assembly between molecular building units.32 Synthons are formed 
following the association or assembly of two molecules via their functional groups by 
interacting with one another in an expected manner by non-covalent interactions. Based on the 
interacting functional groups, there are two principal types of synthons that can be defined: the 
homosynthon and heterosynthon (Figure 1.7). Homosynthons are formed between two 
identical functional groups, while heterosynthons are built from the interaction of different but 
complementary moieties. The functional groups in carboxylic acids, amides or alcohols are 
self-complementary due to the presence of both hydrogen bond donors and acceptors and are 
consequently capable of building homosynthons. Other functionalities have exclusively 
hydrogen bond donors or acceptors, thus these compounds are likely to form heterosynthons 
with compounds that have complementary functional groups.33 Nevertheless, all groups are 
capable to build heterosynthons with other corresponding functional groups. As an example, 
carboxylic acid functional groups, are self-complementary and can assemble together to form 
a homosynthon, whereas the same acid reacting with pyridine, which has a different functional 
group, will result in the formation of a heterosynthon. 
 
                           
Figure 1.7 Supramolecular homosynthon (left) and heterosynthon (right). 
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1.6 Racemic versus chiral crystals 
A Large number of drug targets are enzymes that have chiral active sites, therefore a significant 
number of currently used small molecule drugs are chiral. Chiral drugs, containing at least one 
chiral centre, are extensively considered, but most of the drugs are consumed as racemic blends 
with the same amount of R and S enantiomers. These individual drug enantiomers exhibit 
distinctive pharmacological actions in a chiral domain, like the human body. The fact, that in 
a drug only one of the two enantiomers is responsible for the effectiveness of a treatment, and 
that its counterpart has an unknown pharmacological activity or may present a danger for some 
organs, highlights the fundamental importance of the racemic and the enantiopure 
formulations.34 When new formulations are planned for a selected API, such as co-crystal 
formation or polymorph screening to improve some of the physicochemical properties, 
(melting temperature, solubility, etc.), it is vital to investigate the packing arrangement of the 
new racemic and chiral crystalline solids and understand the differences or similarities of the 
synthon formation of these compounds.35 
According to Wallach’s rule (an empirically deduced rule), the pure enantiomer forms a less 
dense crystal structure than the racemic counterpart.36 From this deduction, Brock ascribed this 
inclination of the racemate to be more stable and denser than their chiral partners, to their ideal 
packing arrangements in racemic space groups in contrast with chiral ones, and not a result of 
any special sorts of interactions between opposite enantiomers.37 While Brock’s conclusion 
was based on single component crystals, Lemmerer et al. examined the single crystal structures 
of two series of co-crystals of chiral carboxylic acids (2-phenylbutyric acid (PBA)), 2-
phenylpropionic (PPA) with isonicotinamide (INA). (R)-PPA and (S)-PPA formed catemers 
(see Figure 1.8).36 (R,S)-PBA rather formed the dimer motif, due to the longer chain of the 
butyric acid in comparison with the propionic acid, requiring a change in motif from catemer 
to dimer, which is the favoured conformation for carboxylic acids with large substituents.38 
The melting point of the racemic co-crystals was found to be higher than the chiral ones, while 
the crystal densities and packing efficiencies shows that the chiral structures pack less closely 
and therefore are expected to have a lower stability and be less thermally stable. 
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Figure 1.8 Representation of dimer (left) and catemer (right) motifs. 
 
1.7 Crystal packing 
The number of molecules in the entire unit cell is denoted as Z, and the symbol Z’ is defined 
as the number of formula units in the crystallographic unit cell divided by the number of 
independent general positions39, which is the amount of molecules in the unit cell divided by 
the group multiplicity or the number of independent general positions.40 The molecules being 
free to bond together in three dimensions in the asymmetric unit is the reason for the complexity 
of that same asymmetric unit, which is different from asymmetric units constrained to operate 
through specific symmetry operations. Besides, the interpretation of what comprises the 
formula unit can be challenging, especially in multicomponent crystals, such as the salt of a 
doubly protonated amine o-phenylenediamine (PDA), with the parameter Z” ( the sum of 
chemical entities within the asymmetric unit41,42) being equal to 26 molecules or charged 
species comprising eight independent o-PDA cations in the asymmetric unit. Therefore, the 
value that must assigned to Z’, regardless of the large value of Z”, is 2. The right value was 
found by neutron diffraction that showed the precise position of the protons. The predicament 
is even more equivocal for nonstoichiometric solvates and inclusion compounds where the 
exact contents of the asymmetric unit may not even be determined.39  Additionally, it is 
fundamental to understand that the Z’ parameter emerges from computational summary of real 
diffraction information and this portrayal might embody an unreliable description of the real 
laboratory condition. For example, crystals with low symmetry space groups, like P1 and Cc 
with Z’>1, were found to be afterwards defined by a greater symmetry model with accordingly 
reduced Z’ number.43 
The parameter Z”, is very important especially for complex crystal structures with ratio that 
cannot be divided in order to give a smaller integer ratio. For instance, the C60 calixarene 
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toluene co-crystal is, a remarkable inclusion complex of formula 
(calix[5]arene)4‧(C60)5‧(toluene)2.44 The structure has a Z’ with the value of 1 and a ratio of 
4:5:2 that cannot be divided to obtain a smaller common denominator, but the Z” = 11 points 
out the complexity of structure. Apart from the mentioned parameters, a third one, Zr, is the 
quantity of distinct kinds of residues (solvents, charged species and neutral compounds).45 To 
explain the crystal packing phenomena of complex structures it is crucial to list explicitly the 
parameters Z’, Z” and Zr.46 Approximately 9.3% of crystals in the CSD crystallise with Z’>1.47 
Some types of compounds, especially chiral molecules show a preference of forming structures 
with high Z’.48  The trend observed was associated with a “frustration” of at least two 
interactions competing during the nucleation process and growth.38 Nevertheless, from 
previous research49,50,51,52 it was concluded that despite the fact that these two factors 
(frustration and nucleation) are important, it is obvious that the variety of structures with high 
Z’ is too large to allow for any extensive generalisation.40 
 
1.8 Aspects of this study 
Based on the literature review presented here and our previous experience in crystal 
engineering, the introduction of chirality when forming new multicomponent crystals is a 
suitable way to alter the crystal packing and eventually the physicochemical properties of the 
new multicomponent crystals.  
The purpose of this research was to design and synthesise first, a set of multicomponent crystals 
where the drug molecule was replaced by a simple chemical unit (phenylsuccinic acid) which 
has limited auxiliary interaction options and conformational motions, while the co-crystallising 
compounds were tertbutylamine, aniline, pyridine, 4-picoline, 2,4-lutidine, 3,4 and 3,5 lutidine 
(Figure 1.9). The mentioned acids and bases were selected due to their capacity to hydrogen 
bond via O-H···N interactions. The second section of the study focused on the synthesis of 
pharmaceutical co-crystals using pyrazinamide (pyrazine carboxamide), an important drug that  
shortens tuberculosis therapy53 as an API while the co-crystallising compound or coformer was 
phenylsuccinic acid. Phenylsuccinic acid was used in the form of a racemic mixture, and in an 
optically active enantiomer (S) form, for both model and pharmaceutical co-crystals. After 
obtaining the desired single crystals, the aim was the examination of the synthesised crystalline 
structures via the synthons formed within them to understand the effect of the racemic and 
chiral crystal arrangement. 
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ACIDS 
 
                                       (R,S)-PSA                   (S)-PSA 
 
BASES 
 
 
Figure 1.9 Structural line diagrams of  acids (rac-phenylsuccinic acid: (R,S)-PSA;  S-
phenylsuccinic acid: (S)-PSA), and bases (Tertbutylamine: TBA; Aniline: ANI; pyridine: 
PYR; 4-methylpyridine: 4-PIC; 2,4-dimethylpyridine: 2,4-LUT; 3,4-dimethylpyridine: 3,4-
LUT; 3,5-dimethylpyridine: 3,5-LUT; pyrazine carboxamide: PCA). 
 
TBA 
                                                                                                                                                                                                                                      
               ANI             PYR                                                        4-PIC 
                                                                                                                                                  
     2,4 LUT                                                  3,4 LUT                                                   3,5-LUT                        
               
                                                                     
  PCA 
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2.1 Experimental methods 
2.1.1 Crystallisation and crystal growth 
Crystallisation is a supramolecular process, therefore a crystal is a product of a supramolecular 
reaction and essentially a kinetic phenomenon. There are different crystallisation techniques 
for molecular solids, such as sublimation, mechanochemistry, melt cooling and solvent 
evaporation, which is the technique that was mostly used. The process of crystallisation is a 
complicated one and can be split into two main steps, known as nucleation and crystal growth.  
2.1.2 Crystallisation procedure 
The multicomponents crystals were synthesised by dissolving the solid acid (R,S-PSA or S-
PSA) in the liquid bases, while the pharmaceutical co-crystal was synthesised by dissolving 
the 1:1 mixture of the solid API (pyrazine carboxamide) and the solid acid (rac-PSA or S-PSA) 
in different solvents with known properties such as, polarity (P) and molecular size (N, Å), see 
Table 2.1. The mixtures were gently heated to 40-50℃ on a hot plate while stirring for the 
solutions to be clear. After homogenisation, the solutions were allowed to cool down before 
filtration through a 0.45μm syringe filter into new vials and left for slow evaporation. 
 
Table 2.1  List of successful solvents including polarity (P) and molecular size (N, Å).1 
Solvent Polarity (P) Molecular size (Na) 
Dichloromethane 3.4 0.460 
Methanol 5.1 0.408 
Tetrahydrofuran 4.2 0.504 
aMolecular size (N) indicates the real size of solvent molecules. Data taken from reference 1. 
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2.1.3 Thermal Analysis 
Differential scanning calorimetry and thermogravimetry were done on a Perkin-Elmer® DSC 
6000 series and a Perkin-Elmer® Pyris 6 series respectively. DSC and TG instruments were run 
with the inert gas N2 with a flow rate of 30 mL.min
-1 and constant heating rate of 10℃.min-1. 
The multicomponent crystals were extracted from their respective solvents, cautiously dried 
with a filter paper, reduced to powder with a pestle and mortar and placed in closed pan with 
holes for DSC analysis and open pan for TGA analysis. 
 
a. Differential scanning calorimetry (DSC) 
DSC is a thermoanalytical technique which measures the temperatures and heat flows 
related with changes in material as a function of time and temperature in a controlled 
environment. The results give qualitative and quantitative details about chemical and 
physical changes involving exothermic or endothermic events. DSC can be used for 
determination of crystallinity, melting point, kinetic studies, or glass and phase 
transition. 
When running a DSC measurement, the sample is placed in a vented pan and further 
closed with a lid. The sample holder is placed next to a reference material and they are 
both subjected to the same temperatures. The result of a DSC analysis is a curve, with 
the temperature shown on the x-axis (℃ or K) and the amount of heat transferred 
presented on the y-axis (mW) displaying peaks and troughs to show the distinctive 
endothermic and exothermic changes, respectively.2 The enthalpy of transition can be 
calculated using the curve with the following formula: 
 
∆H= KA 
 
Where:   ∆H = the enthalpy of transition 
K= the calorimetric constant 
A= the area below the curve 
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b. Thermogravimetric analysis (TGA) 
TGA is a method that is used for the determination of compounds experiencing mass 
variation when exposed to thermal stress.3 It is used to analyse the decomposition, 
kinetics and thermal stability of a sample under a diversity of conditions controlled by 
the equipment. Thermogravimetry was used in this work to check the absence or 
presence of solvents in the different multicomponent crystals synthesised. 
 
2.1.4 Fourier Transform Infrared Spectroscopy (FTIR)  
FTIR spectroscopy is a highly reliable and well-known analytical method for bulk property 
analysis. One of the advantages of FTIR spectroscopy is its capacity as an analytical technique 
to acquire spectra from an extensive variety of fluids, gases and solids. FTIR is useful in organic 
chemistry because it allows identification of functional groups due to their absorptions with 
diverse intensities at specific regions of the infra-red spectrum. Identifying the absorptions of 
the functional groups and understanding the spectrum is crucial and will support further 
examinations of the new multicomponent crystals.  
Spectra were collected by a universal attenuated total reflectance infrared spectrometer (ATR-
FTIR) by Perkin Elmer® spectrum 2. 
 
2.1.5   X-ray diffraction  
Diffraction takes place when X-rays are scattered by a periodic array with long-range order, 
generating at specific angles constructive interference. The atoms present in a crystal diffract 
because they are periodically arranged. The distance between the atoms is similar to the 
wavelength of X-ray. Powder X-ray diffraction techniques use this theory to reveal the 
composition of the crystalline materials. The scattering of X-rays from atoms generate a 
diffraction pattern holding details concerning the crystal atomic arrangement.4 
The diffraction is described by Bragg’s law:  
n𝝀 = 2 d sinθ 
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Where:  𝜃 = angle of incidence  
λ = wavelength of the rays  
d = spacing between layers of atoms  
n = integer  
When Bragg’s law is satisfied, “reflected” beams are in phase and interfere constructively  
The powder X-ray diffractometer measurements were performed at the Cape Peninsula 
University of Technology and the single crystal structure measurements were performed at the 
University of Cape Town because of the availability of the instrument.  
a. Powder X-ray diffraction (PXRD)  
PXRD is a powerful and quick technique principally employed for phase determination 
of a crystal structure and able to provide information regarding the size of the unit cell. 
Bulk amount of crystals of interest is carefully reduced to powder and an average 
portion is analysed. To analyse the crystalline material and phases the PXRD at disposal 
was a Bruker® D2 phaser fitted a graphite-monochromated Cu Kα radiation (λ = 1.5418 
Å) at room temperature.5 The obtained pattern of the bulk material was compared to the 
PXRD pattern of the pure starting material and conclusion was drawn based on the level 
of similarity of the two PXRD pattern. 
 
b. Single crystal X-ray diffraction (SCXRD) 
Single crystal diffraction data were collected on a Bruker® Duo APEX II diffractometer 
with a graphite-monochromated Mo Kα radiation (λ = 0.71073 Å) at 173K using an 
Oxford Cryostream 700.6 
Structures were solved using SHELXL-20167 which was run under a graphical user 
interface, X-seed8. The space groups were determined by using the collected intensities 
and pre-determined cell parameters as inputs to program XPREP.9 SHELXL-20166 was 
used to resolve all crystals by direct methods and refinement was done with SHELXL-
20166 by employing full matrix least-squares against F2 for unique reflection.  
 
Ʃw (𝑭𝟎
𝟐 - k𝑭𝒄
𝟐)2 
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The agreement between the observed structure factors (Fo) and the calculated structure 
factors (Fc) was monitored by assessing the residual index R. The residual index R1 is 
the agreement between the observed and calculated structure factors based on F, while 
the residual index, R2, is the agreement based on F
2.  
R1 =  
Ʃ ‖𝑭𝟎|−|𝑭𝒄‖ 
Ʃ|𝑭𝟎|
    R2 = [
Ʃ𝒘 (𝑭𝟎
𝟐− 𝑭𝒄
𝟐)
𝟐
Ʃ𝒘 (𝑭𝟎
𝟐)
𝟐 ]
𝟏
𝟐 
The weighting scheme ѡ was used to yield a constant distribution in terms of a and b, 
and further refined in the final cycles of structure refinement. 
  
w = 
𝟏
𝝈𝟐 (𝑭𝟎
𝟐)+ (𝒂𝑷)𝟐+𝒃𝑷
 
where:  
P = 
𝒎𝒂𝒙(𝟎,𝑭𝟎
𝟐)+ 𝟐 𝑭𝒄
𝟐
𝟑
 
 
SHELXL-20166 refines against F2, which leads to greater deviation of the Goodness of 
Fit (S) from unity than the refinement against F. The Goodness of Fit expression is:  
 
S = [
Ʃ𝒘 ( |𝑭𝟎|
𝟐− |𝑭𝒄|
𝟐)
𝟐
(𝑵− 𝒏𝒑)
𝟐 ]
𝟏
𝟐 
 
 
The hydrogen atoms bound to carbon atoms were placed at idealised positions and 
refined as riding atoms with Uiso (H) = 1.2 Ueq (Ar-H, CH2) or 1.5 Ueq (CH3) of the 
atom to which the H is bound. If it was possible, the H atoms bonded to carboxylic acid, 
amine or amide groups were located in the difference electron density map and their 
coordinates refined freely but their isotropic displacement parameters were fixed (Uiso 
(H) = 1.2 Ueq (O) or Ueq (N)) if it was necessary.  
X-ray powder patterns were calculated using LAZY PULVERIX10 and compared to 
experimental powder patterns for comparison. All crystal packing diagrams were 
generated with POV-RAY11. The program LAYER12 was utilised to test systematic 
absences and space group symmetry. X-Seed was used as a graphical interface for the 
program SHELXL-2016, LAZY PUVERIX, POV-RAY and LAYER. 
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2.1.6 Computing components 
ConQuest: Search engine using the Cambridge Structural Database (CSD) for informative and 
comparative structure details.13 
Platon: A multipurpose analytical tool for crystal structure analysis; calculates all molecular 
parameters for the structures.14 
SADABS (Siemens Area Detector Absorption Corrections): an application in the APEX suite 
used to scale and correct data for absorption collected on a Bruker AXS area detector.15 The 
program is designed to exploit data redundancy, corrects for errors resulting from the variation 
in the volume of crystal, absorption by the crystal support and crystal decay during the 
measurement. 
XPREP: This program determines the space group by reading the raw data file (.raw) and the 
parameter file (.p4p) written by the diffractometer control program, also write the instruction 
file (.ins) and reflection data (hkl).16 
X-Seed: graphical user interface for crystallography and graphical program.8 
Layer is a component of X-Seed. It displays simulated precession photographs of the 
reciprocal lattice levels using the intensity data.12 
LAZY PULVERIX: software which calculates the theoretical powder X-ray diffraction 
pattern from single crystal X-ray diffraction data.10 
Pov-Ray: program which generates graphics.11 
Pov-Label: allows controlling the atom labels on an image rendered using Pov-Ray.11 
Mercury: Analysis software which provides options to aid the investigation and analysis of 
crystal structures. It can import chemical bond types, 2D connection tables and present them 
in 3D illustration, generates packing diagrams, defines and visualises Miller planes and take a 
slice through a crystal in any direction and also displays space group symmetry elements, 
calculates voids based either on contact surface or solvent accessible surface and 
intermolecular potentials, it can also be used to perform a basic gas phase calculation.17 
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2.2  Materials 
2.2.1  Dicarboxylic acids 
(R-S)-Phenylsuccinic acid and (S)-Phenylsuccinic acid were used in this research (Figure 2.1). 
The chemical structures, molar masses and melting points of these weak acids are listed in 
Table 2.2. 
Figure 2.1 Chemical structures of (R,S) and (S)-Phenylsuccinic acid 
Table 2.2 Physical properties of the dicarboxylic acids (PSA) 
 
Host Formula Mr (g.mol-1) Mp (°C) 
(R,S)-PSA C10H10O4 194.19 165-168 
(S)-PSA C10H10O4 194.19 173-176 
 
 
 
 
 
 
 
 
 
 
  
a) (R,S)-Phenylsuccinic acid, (rac-PSA) b) (S)-Phenylsuccinic acid, (S-PSA) 
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2.2.2  Coformers 
Tertbutylamine (TBA), aniline (ANI), pyridine (PYR), 4-picoline (4PIC), 2,4-Lutidine 
(2,4LUT), 3,4-lutidine (3,4LUT), 3,5-lutidine (3,5LUT) and pyrazine carboxamide (PCA) 
were bought from Sigma-Aldrich and Merck & Co (Figure 2.2). The chemical structures as 
well as the molecular mass, boiling and melting point of the amines and the amide PCA are 
listed in Table 2.3. The amines are used for the synthesis of the multicomponent crystals while 
the amide PCA is used for the synthesis of pharmaceutical co-crystals. The amines used for 
this research are derivatives of pyridine and differ by the position and number of the methyl 
groups on the phenyl ring to study their effect on the crystal packing. The chemical structures 
of the coformers are shown in Figure 2.2. 
 
 
Figure 2.2 Chemical structures of coformers (Tertbutylamine: TBA; Aniline: ANI; pyridine: 
PYR; 4-methylpyridine: 4-PIC; 2,4-dimethylpyridine: 2,4-LUT; 3,4-dimethylpyridine: 3,4-
LUT; 3,5-dimethylpyridine: 3,5-LUT) and the API (pyrazine carboxamide: PCA). 
                                                                                                 
          TBA                                         ANI                                       PYR                                      4-PIC 
 
                                                                 
                         2,4 LUT                                  3,4 LUT                                 3,5-LUT                        
               
 
      PCA 
 
Figure 2.2 Chemical structures of amines and amide guest compounds. 
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Table 2.3 Physical properties of coformers 
Coformer Formula Mr (g.mol-1) Bp (°C) Mp (°C) 
TERTBUTYLAMINE C4H11N 73.14 44-46 n/a 
ANILINE C6H7N 93.13 183-184 n/a 
PYRIDINE C5H5N 79.10 115-116 n/a 
4-PICOLINE C6H7N 93.13 144-145 n/a 
2,4-LUTIDINE C7H9N 107.15 160-161 n/a 
3,4-LUTIDINE C7H9N 107.15 163-164 n/a 
3,5-LUTIDINE C7H9N 107.15 169-170 n/a 
PYRAZINE CARBOXAMIDE C5H5N3O 123.11 n/a 357 
#: Amines and amide are damaging to skin, eyes and respiratory tract. They are dangerous if 
swallowed; if in contact with skin and if breathed in. Important signs for eyes are redness and 
pain, for skin is redness and scalded feeling while following ingestion the effects on central 
nervous system can be delayed. 
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The successfulness of all the crystallisation experiments between (R,S)-PSA, (S)-PSA and the 
coformers would have resulted in the formation of sixteen novel crystal structures. However 
due to the cost of (S)-PSA and the lower probability to obtain crystals with the enantiopure 
compared to the racemate, the work plan (Figure 2.3) was first, attempt to obtain crystals with 
the racemic acid, and second, to try with the enantiopure acid. When no crystals were obtained 
from (R,S)-PSA, there was no attempt with (S)-PSA. 
 
 
 
Figure 2.3 Work flow chart for crystallisation experiments. 
 
 
 
 
 
Attempt with
(R,S)-PSA
+ 
coformer
Positive
Attempt with
(S)-PSA
+
coformer
Negative
No attempt with 
(S)-PSA
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This chapter presents all the multicomponent crystals obtained from the crystallisations of 
racemic or enantiopure phenylsuccinic acids with the selected bases (Table 3.1). The naming 
convention of the compounds follows the system, where first the anion and secondly the cation 
is listed. The reason for this somewhat unorthodox style of naming is to keep the common item, 
i.e. the phenylsuccinic acid, in the first place, followed by the actual base, which aids the clarity 
of discussion.  
 
Table 3.1 Summary of crystallisation experiments 
 
3.1 Multicomponent crystal formation of phenylsuccinic acid with primary amines 
 
(R,S)-PSA and (S)-PSA were exposed to primary amines with bulky functional groups (tert-
butylamine and aniline) to aid the crystallisation process.  
 
3.1.1 tert-Butylammonium carbonate: [2tBa+][COO2-] 
Co-crystallisation of (R,S)-PSA with tert-butylamine (tBa) under atmospheric conditions 
produced crystals with unexpected chemical composition. The amine reacted with the 
atmospheric CO2 and formed a carbonate salt. This behaviour is not uncommon in primary 
amines.1,2,3 The [2tBa+][COO2-] crystallised in the trigonal R3̅c space group (No. 167) with ⅓ 
tBa+ and ⅙ COO2- in the ASU (Figure 3.1a). Each oxygen atom hydrogen bonds to two 
neighbouring tBa+ ions via the N3-H1···O5 interaction and its symmetry generated 
counterparts (Figure 3.1b). The hydrophobic and ionic layers are alternating down the [001] 
direction (Figure 3.1c). The crystallographic details and hydrogen bonds for [2tBa+][COO2-] 
are summarised in Tables 3.2 and 3.3. Although great effort was invested in the experimental 
work, the crystallisation of the S-enantiomer of the phenylsuccinic acid with tert-butylamine 
was unsuccessful. 
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Figure 3.1 [2tBa+][COO2-] crystal structure with labelled atoms in the ASU (a), hydrogen bonds between the ions (b) and 
crystal packing view down [100] (c).  
 
Table 3.2 Crystal data for [2tBa+][COO2-], [(R,S)-PSA-][ANI+] and  [(S)-PSA2-] 
[2ANI+]·ANI. 
Crystal data 
Compounds [2tBa+][COO2-] [(R,S)-PSA-][ANI+] [(S)-PSA2-][2ANI+]·ANI 
Molecular formula  C9H24N2O3 C16H17NO4 C28H31N3O4 
Formula weight (g.mol-1) 208.30 287.30 473.56 
Crystal system Trigonal Monoclinic Orthorhombic 
Space group R3̅c (167) Pn(7) P21 (18) 
a (Å) 6.3212(9) 9.5310(19) 25.731(5) 
b (Å) 6.3212(9) 8.3030(17) 8.2594(17) 
c (Å) 53.448(11) 9.885(2) 12.118(2) 
α (°)  90 90 90 
β (°) 90 111.82(3) 90 
γ (°) 120 90 90 
V (Å) 1849.5(6) 726.2(3) 2575.3(9) 
Z 6 2 4 
ρcalc/ g.cm-3 1.122 1.314 1.221 
μ (MoKα) / mm-1 0.083 0.095 0.082 
F (000) 696 304 1008 
Crystal size (mm) 0.07 × 0.38 × 0.40 0.04 × 0.240 × 0.300 0.093 × 0.328 × 0.334 
Temperature (K) 173(2) 173(2) 173(2) 
Radiation [Å] MoKα (0.71073 Å) MoKα (0.71073 Å) MoKα (0.71073 Å) 
Theta min-max [°] 2.286, 28.417 2.453, 28.389 1.583, 27.175 
Dataset -8:7, -8:8, -70:70 -12:12, -11:11, -13:13 -33:32, -10:10, -15:15 
Final R indices [I > 2.0 (I)] R1 = 0.0331, wR2 = 0.0922 R1 = 0.0392, wR2 = 0.0810 R1 = 0.0415, wR2 = 0.0996 
R indices (all data) R1 = 0.0359, wR2 = 0.0946 R1 = 0.0500, wR2 = 0.0862 R1 = 0.0473, wR2 = 0.1028 
Tot., uniq.data, R (int) 4739, 484, 0.0280 10213, 3039 , 0.0316 28838, 5209 , 0.0375 
Nref, Npar 528, 26 3608, 206 5734, 394 
S 1.118 0.992 1.068 
Max. ans av. Shift/error 0.000, 0.000 0.000, 0.000 0.000, 0.000 
Min. and max. resd. Dens (Å3) -0.135, 0.287 -0.179, 0.152 -0.223, 0.177 
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Table 3.3 Hydrogen bonds in [2tBa+][COO2-], [(R,S)-PSA-][ANI+] and  [(S)-PSA2-] 
[2ANI+]·ANI. 
D-H•••A d(D-H) (Å) d(H•••A) (Å) d(D•••A) (Å) D-H•••A (°) Symmetry operator 
[2tBa+][COO2-] 
N3-H1•••O5 0.95 1.79 2.730 170.0  
[(R,S)-PSA-][ANI+] 
N15-H15A•••O10 1.02 1.67 2.675 168.5  
N15-H15B•••O13 0.87 2.36 2.937 124.2 x, y, z+1 
N15-H15B•••O14 0.87 2.34 2.937 126.1 x-1/2, -y+1, z+1/2 
N15-H15C•••O11 0.94 1.77 2.714 177.4 x+1/2, -y+1, z+1/2 
O14-H14•••O11 0.91 1.61 2.523 173.5 x+1/2, -y+1, z-1/2 
[(S)-PSA2-] [2ANI+]·ANI 
C17-H17•••O13 0.95 2.50 3.265 138.1  
N15-H15A•••O13 0.94 2.51 3.024 114.5  
N15-H15A•••O14 0.94 1.81 2.721 163.5  
N15-H15B•••O11 0.93 1.85 2.743 160.4 x, y+1, z 
N22-H22C•••O10 0.95 1.79 2.736 174.0 x, y+1, z 
N22-H22C•••O11 0.95 2.55 3.083 116.0 x, y+1, z 
N22-H22A•••O13 0.91 1.78 2.684 174.4  
N22-H22B•••O10 0.95 1.78 2.723 175.8 -x+1/2, y+1/2, -z 
N29-H29A•••O11 0.87 2.22 3.089 175.4  
N15-H15C•••O14 0.94 1.77 2.709 176.0 -x+1/2, y+1/2, -z+1 
C17-H17•••O13 0.95 2.50 3.265 138.1  
 
 
3.1.2. Anilinium phenylsuccinate: [(R,S)-PSA-][ANI+] 
The crystallisation of the racemic-phenylsuccinic acid from aniline resulted in the [(R,S)-PSA-
][ANI+] salt that crystallised in the monoclinic Pn space group (No. 7) with one mono-
deprotonated PSA- and one ANI+ in the ASU. (The ASU was selected to contain the S-
enantiomer of the PSA. This was done in all of the following racemic structures of PSA to aid 
the easy comparison of molecular conformations.) The deprotonation happened on the 
propanoate end of the molecule (Figure 3.2a) and the N15-H15A···O10 charge assisted 
hydrogen bond is formed. The acid molecules hydrogen bond to each other via the O14-
H12···O11 interaction and the anilinium ions are linking the acid chains by forming three 
hydrogen bonds with neighbouring carboxylic acid and carboxylate functional groups (Figure 
3.2b). The alternating aromatic rings of the hydrogen bonded acids and anilinium ions interlock 
to form the third dimension of the crystal (Figure 3.2c and d). The data collection and 
refinement details as well as hydrogen bonds for [(R,S)-PSA-][ANI+] are summarised in tables 
3.2 and 3.3. 
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Figure 3.2 Crystal structure of [(R,S)-PSA-][ANI+] with labelled atoms of the ASU (a), hydrogen bonds between the ions (b, 
the aromatic rings are faded out to aid a better viewing of the prominent hydrogen bonds) and crystal packing showing the 
interlocking aromatic layers, (c) view down [001] and (d) [100]. 
 
3.1.3. Anilinium (S)-phenylsuccinate aniline solvate: [(S)-PSA2-][2ANI+]·ANI 
The crystallisation of the enantiopure (S)-phenylsuccinic acid from aniline yielded crystals 
with different stoichiometry than observed during the crystallisation of the racemic acid. The 
structure may be classified as a salt-solvate since it contains a double deprotonated 
phenylsuccinic acid [(S)-PSA2-], two anilinium ions and one neutral aniline in the ASU (Figure 
3.3a). The [(S)-PSA2-][2ANI+]·ANI crystallised in the orthorhombic P21212 space group (No. 
18). Crystal data, refinement details and hydrogen bonds of [(S)-PSA2-][2ANI+]·ANI are 
summarised in Tables 3.2 and 3.3 
The PSA2- ion is disordered in two positions in a 70-30% distribution. The minor disorder is 
shown with light blue colouring on Figure 3.3a and is omitted from the following packing 
diagrams for clarity. The PSA2- ions are hydrogen bonding to neighbouring anilinium ions via 
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N-H···O interactions and forming rings that may be described by the 𝑅4
4(12) graph set (Figure 
3.3b). The hydrogen bonding extends via the -NH3
+ moiety to form layers of ions (Figure 3.3b, 
green arrows). The neutral aniline molecules are interacting with the carboxylate groups via 
N29-H29A···O11 interactions that are not ideal geometrically. These loosely bonding solvent 
molecules are embedded between the aromatic rings of the hydrogen bonded ions (Figure 3.3c, 
yellow space fill model). Contrary to the racemic structure, here, the layers that are formed 
from the hydrogen bonded ions and the neutral aniline molecules, do not interlock with each 
other and form non-polar layers built from two layers of aromatic rings in the crystal (Figure 
3.3d).  
The difference between the crystal structures of the racemic and the chiral salts obtained from 
crystallisation of PSA from aniline, [(R,S)-PSA-][ANI-] and [(S)-PSA2-][2ANI+]·ANI is 
significant. The structures differ in (1) the deprotonation of the acid, (2) the stoichiometric ratio 
of crystallisation and (3) the hydrogen bonds formed in the crystals. While packing differences 
between racemic and their chiral counterparts are expected to occur because of the different 
molecular shapes of these molecular building blocks, the difference in their deprotonation is 
unexpected, since the pKa values of the enantiomers are the same.  
 
Figure 3.3 Crystal structure of [(S)-PSA2-][2ANI+]·ANI with labelled contact atoms of the ASU (a) and the hydrogen bonds 
between the ions (b, the aromatic rings are faded out to aid a better viewing of the prominent hydrogen bonds and green 
arrow represent the extending hydrogen bonds). The aniline molecules are embedded between the aromatic rings of the 
hydrogen bonded ions (c, yellow space fill model). The aromatic rings of the hydrogen bonded layers (d, blue and red) do 
not interlock with neighbouring ones. 
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3.2 Multicomponent crystal formation of phenylsuccinic acid with aromatic amines 
 
(R,S)-PSA and (S)-PSA were exposed to pyridine and a series of methyl substituted aromatic 
amines. The racemic acid was crystallised successfully with pyridine (PYR), 4-picoline (4PIC) 
and 2,4-lutidine (2,4LUT). Crystallisation from 3,4-lutidine (3,4LUT) and 3,5-lutidine 
(3,5LUT) was successful with both the racemic and the S-enantiomer of PSA. 
 
3.2.1 (R,S)-Phenylsuccinic acid pyridine solvate: (R,S)-PSA·2PYR 
(R,S)-PSA crystallised with two equivalent of PYR in the centrosymmetric 𝑃1̅ (No. 2) space 
group (Figure 3.4a). The crystal data and hydrogen bonds for (R,S)-PSA·2PYR are listed in 
Tables 3.4 and 3.5. The PSA molecule is in a different conformation when compared to the 
previously described structures. The succinic acid backbone was linear in the previous cases, 
while here, this moiety takes up a ‘bent’ conformation. The details of the conformational 
changes observed in all the multicomponent crystals of PSA presented in this thesis are 
discussed in chapter 4. There was no proton transfer observed between the acid and the base 
and the formation of the acid-base heterosynthon via two hydrogen bonds, described as 𝑅2
2(7) 
graph set, was noted. Molecule A of the PYR is coplanar with the related carboxylic acid group 
(∡17.2°) but molecule B is 31.7° out of plane with the related acid moiety. Nevertheless, the 
interaction between molecule B and the acid occurred through two hydrogen bonds, between 
the ortho hydrogen (H22) and the carbonyl oxygen atom (2.66 Å). The neighbouring acids 
interact via C8-H8A···O11 hydrogen bond and its symmetry generated counterpart, forming 
𝑅2
2(8) rings. There are also weak C17-H17···O10 hydrogen bonds formed between the adjacent 
base-acid-base (BAB) units (Figure 3.4b). Overall, the crystal has a layered structure, where 
the alternating sheets of the solvent molecules and the acids form layers parallel to the (010) 
plane (Figure 3.4c).  
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Figure 3.4 Crystal structure of (R,S)-PSA·2PYR with hydrogen bonds and labelled contact atoms of the ASU (a). The 
neighbouring base-acid-base (BAB) units hydrogen bond via C8-H8A···O11 and its symmetry generated counterpart and 
weak C17-H17···O10 interactions between the pyridine and the carbonyl oxygen atoms (b). The solvent molecules (blue and 
red) are packed in layers that are parallel with the (010) and (001) planes (c). 
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Table 3.4 Crystal data for (R,S)-PSA·2PYR, (R,S)-PSA·2(4PIC) and (R,S)-
PSA·2(2,4LUT). 
Crystal data 
Compounds (R,S)-PSA·2PYR (R,S)-PSA·2(4PIC) (R,S)-PSA·2(2,4LUT) 
Molecular formula  C20H20N2O4 C22H24N2O4 C24H28N2O4 
Formula weight (g.mol-1) 352.38 380.43 408.48 
Crystal system Triclinic Monoclinic Monoclinic 
Space group P1̅ (2) P21/c (14) P21/c (14) 
a (Å) 5.6697(4) 22.906(5) 11.773(2) 
b (Å) 10.5672(6) 5.7441(11) 8.4930(17) 
c (Å) 15.5754(10) 15.376(3) 22.318(5) 
α (°)  109.3480(10) 90 90 
β (°) 96.6060(10) 100.98(3) 96.22(3) 
γ (°) 91.6060(10) 90 90 
V (Å) 872.44(10) 1986.1(7) 2218.4(8) 
Z 2 4 4 
ρcalc/ g.cm-3 1.341 1.272 1.223 
μ (MoKα) / mm-1 0.094 0.088 0.083 
F (000) 372 808 872 
Crystal size (mm) 0.010×0.010×0.010 0.080×0.110×0.210 0.180×0.380×0.570 
Temperature (K) 173(2) 173(2) 173(2) 
Radiation [Å] MoKα (0.71073 Å) MoKα (0.71073 Å) MoKα (0.71073 Å) 
Theta min-max [°] 1.398, 27.532 1.811, 27.131 1.740, 28.452 
Dataset -7:7, -13:13, -20:20 -29:29, -7:3, -19:19 -15:15, -11:11, -28:29 
Final R indices [I > 2.0 (I)] R1=0.0359, wR2=0.0885 R1=0.0782, wR2=0.1954 R1=0.0545, wR2=0.1303 
R indices (all data) R1=0.0389, wR2=0.0907 R1=0.1345, wR2=0.2287 R1=0.0822, wR2=0.1464 
Tot., uniq.data, R (int) 23333, 3681 , 0.0223 11159, 2529 , 0.0316 25976, 3832, 0.0242 
Nref, Npar 4011, 243 4367, 278 5492, 353 
S 1.059 1.035 1.025 
Max. ans av. Shift/error 0.001, 0.000 0.000, 0.000 0.000, 0.000 
Min. and max. resd. Dens (Å3) -0.135, 0.287 -0.283, 0.473 -0.270, 0.256 
 
Table 3.5 Hydrogen bonds in (R,S)-PSA·2PYR, (R,S)-PSA·2(4PIC) and (R,S)-
PSA·2(2,4LUT). 
D-H•••A d(D-H) (Å) d(H•••A) (Å) d(D•••A) (Å) D-H•••A (°) Symmetry operator 
(R,S)-PSA·2PYR 
C8-H8A•••O11 0.99 2.55 3.356 138.7 -x+2, -y+2, -z+1 
O11-H11•••N15 0.95 1.68 2.625 174.4  
O14-H14•••N21 0.91 1.80 2.700 174.6  
C17-H17•••O10 0.95 2.53 3.427 158.6 -x+1, -y+1, -z+1 
C22-H22•••O13 0.95 2.66 3.308 126.1  
(R,S)-PSA·2(4PIC) 
C23-H23•••O11Bb 0.84 2.43 2.974 123.5  
O11Aa-H14A•••N22 0.84 1.77 2.597 166.5  
O14Aa-H14A•••N15 0.84 1.87 2.704 177.0  
O11Bb-H11B•••N22 0.84 2.33 2.938 129.2  
(R,S)-PSA·2(2,4LUT) 
O11-H11•••N23 1.03 1.59 2.610 168.2  
O14-H14•••N15 1.03 1.56 2.587 174.2  
C19-H19•••O10 0.95 2.50 3.379 154.3 x+1, y, z 
C20-H20•••O13 0.95 2.64 3.305 127.6  
C27d-H27d•••O13 0.95 2.53 3.463 167.3 x+1, y, z 
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3.2.2. (R,S)-Phenylsuccinic acid 4-picoline solvate: (R,S)-PSA·2(4PIC) 
 
(R,S)-PSA crystallised with two equivalents of 4PIC in the centrosymmetric P21/c (No. 14) 
space group (Figure 3.5a). (For crystallographic details and hydrogen bonds see Tables 3.4 and 
3.5.) The succinic acid backbone is linear but disordered in two positions and the major disorder 
occupies 82% of the positions. Both of the carboxylic acid groups are disordered in two 
positions also and their site occupancy was set the same as the disorders of the backbone. (The 
minor disorder is represented in wireframe style on Figure 3.5a.) The structure is a solvate, i.e. 
no proton has been transferred from the acid to the base. This decision was made based on the 
analysis of the C-O bond length. Some of these bond lengths were close to 1.3 Å (in case of 
C9-O11A, C9-O11B, C12-O14A and C12-O14B), thus these were treated as C-OH groups and 
hydrogen atoms were added with the appropriate restrains. The length of the complementary 
C-O bonds was closer to 1.2 Å that are in the region of the C=O double bond (C9-O10A, C9-
O10B, C12-O13A and C12-O13B). To support the decision based on the C-O bond length, 
there was no protonation observed of the nitrogen atoms of the 4-picolines. The minor disorders 
of the carboxylic acid groups are not representing chemically meaningful positions; therefore, 
structural description of the crystal will focus on the interactions of the main disorder model.  
The PSA molecule forms the well-known acid- amine(ar) heterosynthon via O11A-H11A···N22 
and C23-H23···O10A, described with 𝑅2
2(7) graph set, and forms a single hydrogen bond via 
O14A-H14A···N15 with the other 4PIC. These T-shape molecular base-acid-base (BAB) units 
form molecular tapes where the distance between the planes fitted to the 4PICs are 3.25 Å and 
3.58 Å (Figure 3.5b, green and yellow highlights, respectively). These values are in the region 
of the typical π···π interactions and although the 4PIC molecules are parallel to one another 
the rings are offset. These molecular tapes are in a 45.9° angle when view down [001] (Figure 
3.5c). The two symmetry independent 4PIC molecules are packed in a slightly different manner 
in the crystal when forming the layered structure. One of the 4PIC (molecule A, represented 
with blue on Figure 3.5d) shows better overlap with neighbouring molecules than the other 
4PIC (molecule B, red on Figure 3.5d). This subtle difference in the packing environment 
cannot be clearly seen on the thermal behaviour of the crystal; the release of the two 4PIC 
molecules happen in one step during the TGA analysis (Figure E.2, Appendix). 
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Figure 3.5 Crystal structure of (R,S)-PSA·2(4PIC) with labelled contact atoms of the ASU and showing the minor disorder of 
the acid with wireframe presentation (a). The T-shape base-acid-base (BAB) units form molecular tapes (b) that are in 45.9° 
angle (c) when view down [001]. The layered structure of the crystal (d) where molecules are coloured according to 
symmetry equivalence.  
 
3.2.3 (R,S)-Phenylsuccinic acid 2,4-lutidine solvate: (R,S)-PSA·2(2,4LUT) 
 
(R,S)-PSA crystallised with two equivalent of 2,4LUT in the centrosymmetric P21/c (No. 14) 
space group (Figure 3.6a). (For crystal structure data and hydrogen bonds see tables 3.4 and 
3.5.) The structure is a solvate, i.e. no proton has been transferred from the acid to the base. 
The conformation of the succinic acid backbone is linear, similar to that seen in the previous 
crystal structure, and disordered in two positions. The major disorder occupies ca. 75% of the 
positions. (The minor disorder is represented in wireframe style on Figure 3.6a.) Contrary to 
(R,S)-PSA·2(4PIC), the carboxylic acid groups are ordered in this structure and their hydroxyl 
hydrogens were located in the electron density map. (H11 and H14 were restrained during the 
refinement process to reach convergence.) The two carboxylic acid groups form acid- amine(ar) 
heterosynthons with 2,4LUT molecules via pairs of hydrogen bonds (O14-H14···N15 and C20-
H20···O13 with molecule A, and O11A-H11A···N23 and C28-H28···O10 with molecule B) 
that can be described with the 𝑅2
2(7) graph set (Figure 3.6a). Three out of the four methyl groups 
of the 2,4LUT molecules are disordered and were refined using appropriate restraints (two 
positions were refined with equal site occupancies).  
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The neighbouring T-shape BAB units interact via hydrogen bonds formed between the 
carbonyl oxygen of the acid and the C-H hydrogen atoms of the 2,4LUT molecules (C19-
H19···O10 and C27-H27···O13, Figure 3.6b). Also, similarly to the (R,S)-PSA·2(4PIC) 
structure, the BAB units interact with neighbouring ones via π···π interactions formed between 
their overlapping symmetrically identical 2,4LUT molecules with a centroid distance of 3.51 
Å (Figure 3.6c, green highlights between two molecules A, coloured blue). π···π interactions 
occurs only between these pairs of molecules. The overlap is not perfect between the symmetry 
independent 2,4LUT molecules because of the lack of their parallel arrangement and the offset 
positions. The layered nature of the crystal packing is similar to the (R,S)-PSA·2(4PIC) 
structure but the symmetrically independent 2,4LUT molecules are in the same layer (Figure 
3.6d). 
 
 
Figure 3.6 Crystal structure of (R,S)-PSA·2(2,4LUT) with labelled contact atoms of the ASU and showing the minor disorder 
of the acid with wireframe presentation (a). The T-shape base-acid-base (BAB) units form hydrogen bonded molecular tapes 
(b) and aromatic interactions (c) with neighbouring counterparts. The layered structure of the crystal (d) where molecules 
are coloured according to symmetry equivalence. 
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3.2.4 (R,S)-Phenylsuccinic acid 3,4-lutidine solvate: (R,S)-PSA·2(3,4LUT) 
 
(R,S)-PSA crystallised with two equivalent of 3,4LUT in the centrosymmetric 𝑃1̅ (No. 2) space 
group (Figure 3.7a). The succinic acid backbone of the PSA molecule is ‘bent’. There was no 
proton transfer observed between the acid and the base, and the formation of the acid-base 
heterosynthon with one of the base molecules (B) via two hydrogen bonds, described as 𝑅2
2(7) 
graph set, was noted. The other base (molecule A) forms only a single hydrogen bond with the 
acid. (See tables 3.6 and 3.7 for crystallographic data and hydrogen bonds.) The structural 
arrangement of the ASU resembles (R,S)-PSA·2PYR, but one of the base (molecule A) forms 
only a single hydrogen bond with the related carboxylic acid moiety because they are out of 
plane (∡ 22.3°). Subsequently, a longer distance was observed between the carbonyl oxygen 
and the ortho hydrogen atom (2.79 Å). The two structures also differ in the next level of 
interactions formed between the BAB units with neighbouring symmetry equivalents. The units 
interact via the formation of 𝜋-stacking between like lutidine moieties (see blue and red pair of 
molecules on Figure 3.7b). The pair of lutidines (molecule A, blue) are parallel to one another 
(3.45 Å) but positioned in slightly offset with the two centroids distanced to 3.87 Å, while the 
other pair (molecule B, red) are situated showing a better overlap (plane distance: 3.42 Å, 
distance of centroids: 3.52 Å). The crystal has a layered structure, where the alternating sheets 
of the symmetrically identical solvent molecules and the acids form layers parallel to the (010) 
plane (Figure 3.7c). 
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Figure 3.7 Crystal structure of (R,S)-PSA·2(3,4LUT) with hydrogen bonds and labelled contact atoms of the ASU (a). The 
neighbouring base-acid-base (BAB) units hydrogen bond via C22-H22C···O14 and its symmetry generated counterpart and 
𝜋-interactions between the 3,4LUTs (b). The solvent molecules (blue and red) are packed in separate layers that are 
parallel with the (001) plane (c). 
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Table 3.6 Crystal data for (R,S)-PSA·2(3,4LUT), 2(S)-PSA·4(3,4LUT), [(R,S)-PSA2-] 
2[3,5LUT+]·2(R,S)-PSA and 2[(S)-PSA2-]4[3,5LUT+]·4(S)-PSA. 
Crystal data  
Compounds (R,S)-PSA·2(3,4LUT) 2(S)-PSA·4(3,4LUT) [(R,S)-PSA2-] 
2[3,5LUT+]·2(R,S)-PSA 
2[(S)-PSA2-] 
4[3,5LUT+]·4(S)-PSA 
Molecular formula  C24H28N2O4 C28H28N2O4 C24H28N2O4 C88H96N4O24 
Formula weight (g.mol-1) 408.48 408.48 408.48 1593.68 
Crystal system Triclinic Triclinic Monoclinic Triclinic 
Space group P1̅ (2) P1 (1) P21/c (14) P1 (1) 
a (Å) 7.0626(14) 7.1918(14) 12.222(2) 8.3469(17) 
b (Å) 8.7704(18) 8.7570(18) 14.926(3) 12.268(3) 
c (Å) 18.630(4) 18.766(4) 22.984(5) 20.595(4) 
α (°)  90.98(3) 89.75(3) 90 84.66(3) 
β (°) 100.42(3) 79.83(3) 103.42(3) 86.58(3) 
γ (°) 107.25(3) 72.07(3) 90 76.63(3) 
V (Å) 1080.8(4) 1105.2(4) 4078.4(15) 2041.2(8) 
Z 2 2 4 1 
ρcalc/ g.cm-3 1.255 1.227 1.298 1.296 
μ (MoKα) / mm-1 0.086 0.084 0.095 0.095 
F (000) 436 436 1688 844 
Crystal size (mm) 0.140 × 0.220 × 0.480 0.100 × 0.100 × 0.100 0.100 × 0.200 × 0.240 0.200 × 0.240 × 0.500 
Temperature (K) 173(2) 173(2) 173(2) 173(2) 
Radiation [Å] MoKα (0.71073 Å) MoKα (0.71073 Å) MoKα (0.71073 Å) MoKα (0.71073 Å) 
Theta min-max [°] 2.229, 28.450 4.015, 26.707 1.640, 27.610 1.712, 28.361 
Dataset -9:9, -11:10, -24:24 -9:9, -11:11, -23:23 -14:15, -19:19, -29:29 -11:11, -16:16, -27:26 
Fin. R ind. [I > 2.0 (I)] R1 = 0.0513, wR2 = 0.1213 R1 = 0.0647, wR2 = 0.1511 R1 = 0.0696, wR2 = 0.1655 R1 = 0.0768, wR2 = 0.1977 
R indices (all data) R1 = 0.0683, wR2 = 0.1313 R1 = 0.1152, wR2 = 0.1786 R1 = 0.1101, wR2 = 0.1906 R1 = 0.1012, wR2 = 0.2177 
Tot., uniq.data, R (int) 12233, 4166 , 0.0265 9225, 5940, 0.075 51410, 6132, 0.0506 46913, 14901, 0.0269 
Nref, Npar 5423, 284 9225, 546 9432, 609 19773, 1062 
S 1.057 1.023 1.030 1.019 
Max. ans av. Shift/error 0.000, 0.000 0.000, 0.000 0.000, 0.000 0.000, 0.000 
Min. and max. resd. 
Dens (Å3) 
-0.277, 0.535 -0.338, 0.428 -0.432, 0.933 -0.503, 0.725 
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Table 3.7 Hydrogen bonds in (R,S)-PSA·2(3,4LUT), 2(S)-PSA·4(3,4LUT), [(R,S)-PSA2-] 
2[3,5LUT+]·2(R,S)-PSA and 2[(S)-PSA2-]4[3,5LUT+]·4(S)-PSA. 
D-H•••A d(D-H) 
(Å) 
d(H•••A) 
(Å) 
d(D•••A) 
(Å) 
D-H•••A (°) Symmetry 
operator 
(R,S)-PSA·2(3,4LUT) 
N15-H15•••O10 0.92 2.58 3.192 123.9  
N15-H15•••O11 0.92 1.83 2.756 176.0  
C16-H16•••O10 0.95 2.50 3.150 125.3  
C16-H16•••O10Y 0.95 2.26 3.148 155.8 x-1, y, z 
C20-H20•••O13Y 0.95 2.35 3.204 148.7  
N23-H23•••O14 0.92 2.60 3.210 124.3  
N23-H23•••O14 0.92 1.80 2.722 179.3  
C24-H24•••O10X 0.95 2.31 3.143 146.4 -x, y-1/2, -z+1/2 
C28-H28•••O13 0.95 2.46 3.132 127.3  
C28-H28•••O13X 0.95 2.39 3.267 152.5 -x+1, y-1/2, -z+1/2 
C1Aa-H1A•••O14Y 1.00 2.51 3.342 153.8  
C8Aa-H8A1•••O11X 0.99 2.43 3.342 152.6 -x, y-1/2, -z+1/2 
C1Bb-H1B•••O11X 1.00 2.34 3.292 158.5 -x, y-1/2, -z+1/2 
C8Bb-H8B1•••O14Y 0.99 2.48 3.428 160.6  
O14Y-H14Y•••O11 0.87 1.73 2.586 170.7  
O14X-H14X•••O13 0.91 1.69 2.593 176.9 -x+1, y+1/2, -z+1/2 
O11Y-H11Y•••O10 0.89 1.73 2.611 171.3 x+1, y, z 
O11X-H11X•••O14 0.98 1.62 2.600 174.4 -x, y+1/2, -z+1/2 
2(S)-PSA·4(3,4LUT) 
C1A-H1A•••O11X 1.00 2.41 3.356 157.6  
C8A-H8B•••O11Y 0.99 2.46 3.246 135.9 x, y-1, z 
N15A-H15A•••O13A 0.88 1.82 2.692 173.3  
N15A-H15A•••O14A 0.88 2.62 3.208 124.7  
C16A-H16A•••O10Y 0.95 2.38 3.238 149.5 x, y-1, z 
C20A-H20A•••O14A 0.95 2.54 3.180 125.0  
C20A-H20A•••O13Y 0.95 2.38 3.235 149.4  
N23A-H23A•••O14A 0.88 1.85 2.717 170.2  
C24A-H24A•••O10A 0.95 2.51 3.168 126.3  
C24A-H24A•••O13X 0.95 2.34 3.212 153.0 x, y-1, z 
C28A-H28A•••O10X 0.95 2.39 3.232 147.9  
N15B-H15B•••O10X 1.10 1.56 2.631 165.1  
C16B-H16B•••O10Z 0.95 2.33 3.194 150.3  
C20B-H20B•••O13Z 0.95 2.31 3.183 155.7 x, y-1, z 
N23B-H23B•••O11B 0.76 1.92 2.667 171.8  
C24B-H24B•••O10W 0.95 2.31 3.209 158.7  
C28B-H28B•••O13W 0.95 2.22 3.059 146.5 x, y-1, z 
O11W-H11W•••O10B 0.84 1.82 2.656 176.8  
O14W-H14W•••O11B 0.84 1.82 2.654 173.6 x, y+1, z 
O11X-H11X•••O11A 0.84 1.72 2.558 174.6  
O14X-H11X•••O10A 0.84 1.78 2.612 170.1 x, y+1, z 
O11Y-H11Y•••O13A 0.84 1.74 2.573 174.4 x, y+1, z 
O14Y-H11Y•••O14A 0.84 1.73 2.566 174.0  
O11Z-H11Z•••O13B 0.84 1.79 2.611 165.5  
O14Z-H14Z•••O14B 0.84 1.88 2.709 170.2 x, y+1, z 
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[(R,S)-PSA2-] 2[3,5LUT+]·2(R,S)-PSA 
N15-H15•••O10 0.92 2.58 3.192 123.9  
N15-H15•••O11 0.92 1.83 2.756 176.0  
C16-H16•••O10 0.95 2.50 3.150 125.3  
C16-H16•••O10Y 0.95 2.26 3.148 155.8 x-1, y, z 
C20-H20•••O13Y 0.95 2.35 3.204 148.7  
N23-H23•••O13 0.92 2.60 3.210 124.3  
N23-H23•••O14 0.92 1.80 2.722 179.3  
C24-H24•••O10X 0.95 2.31 3.143 146.4  
C28-H28•••O13 0.95 2.46 3.132 127.3  
C28-H28•••O13X 0.95 2.39 3.267 152.5 x+1, y, z 
C1Aa-H1A•••O14Y 1.00 2.51 3.342 153.8  
C8Aa-H8A1•••O11X 0.99 2.43 3.342 152.6  
C1Bb-H1B•••O11X 1.00 2.34 3.292 158.5  
C8Bb-H8B1•••O14Y 0.99 2.48 3.428 160.6  
O14Y-H14Y•••O11 0.87 1.73 2.586 170.7  
O14X-H14X•••O13 0.91 1.69 2.593 176.9 x-1, y, z 
O11Y-H11Y•••O10 0.89 1.73 2.611 171.3 x+1, y, z 
O11X-H11X•••O14 0.98 1.62 2.600 174.4  
2[(S)-PSA2-]4[3,5LUT+]·4(S)-PSA 
C1A-H1A•••O11X 1.00 2.41 3.356 157.6 x, y+1, z 
C8A-H8B•••O11Y 0.99 2.46 3.246 135.9 x, y-1, z 
N15A-H15A•••O13A 0.88 1.82 2.692 173.3  
N15A-H15A•••O14A 0.88 2.62 3.208 124.7  
C16A-H16A•••O10Y 0.95 2.38 3.238 149.5 x, y-1, z 
C20A-H20A•••O14A 0.95 2.54 3.180 125.0  
C20A-H20A•••O13Y 0.95 2.38 3.235 149.4  
N23A-H23A•••O11A 0.88 1.85 2.717 170.2  
C24A-H24A•••O10A 0.95 2.51 3.168 126.3  
C24A-H24A•••O13X 0.95 2.34 3.212 153.0  
C28A-H28A•••O10X 0.95 2.39 3.231 147.9 x, y+1, z 
N15B-H15B•••O13B 1.10 1.56 2.631 165.1  
C16B-H16B•••O10Z 0.95 2.33 3.194 150.3 x, y+1, z 
C20B-H20B•••O13Z 0.95 2.31 3.183 155.7  
N23B-H23B•••O11B 0.76 1.92 2.667 171.8  
C24B-H24B•••O10W 0.95 2.31 3.209 158.7  
C28B-H28B•••O13W 0.95 2.22 3.059 146.5 x, y-1, z 
O11W-H11W•••O10B 0.84 1.82 2.656 176.8  
O14W-H14W•••O11B 0.84 1.82 2.654 173.6 x, y+1, z 
O11X-H11X•••O11A 0.84 1.72 2.558 174.6 x, y-1, z 
O14X-H11X•••O10A 0.84 1.78 2.612 170.1  
O11Y-H11Y•••O13A 0.84 1.74 2.573 174.4 x, y+1, z 
O14Y-H11Y•••O14A 0.84 1.73 2.566 174.0  
O11Z-H11Z•••O13B 0.84 1.79 2.611 165.5 x, y-1, z 
O14Z-H14Z•••O14B 0.84 1.88 2.709 170.2  
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3.2.5 (S)-Phenylsuccinic acid 3,4-lutidine solvate: 2(S-PSA)·4(3,4LUT) 
 
(S)-PSA crystallised with two equivalent of 3,4LUT in the non-centrosymmetric P1 (No. 1) 
space group. The ASU contains two PSA and four 3,4LUT neutral molecules (Figure 3.8a). 
Similar to the racemic structure, the succinic acid backbone of both PSA molecules is ‘bent’. 
The two symmetrically independent BAB units (Figure 3.8a) differ slightly in their hydrogen 
boding. The unit that is formed by molecule A of (S)-PSA is disordered in the position of one 
of the 3,4LUT (58% S.O.F. for the main disorder) and the related acid moiety (60% occupied 
by the main disorder). This unit has only single hydrogen bonds formed between the acid and 
the bases. The other BAB unit (formed by molecule B of (S)-PSA) is ordered and the hydrogen 
bonding formed between the acid and the base moieties can be described as the 𝑅2
2(7) graph 
set. (For crystallographic details of the structure and hydrogen bonds see Tables 3.6 and 3.7.) 
The structural arrangement of the crystal resembles the (R,S)-PSA·2(3,4LUT) in that the BAB 
units are interacting via the formation of 𝜋-stacking between the lutidine moieties (see dark 
and lighter blue and dark and lighter red pairs of molecules on Figure 3.8b). The 3,4LUT 
molecules are not parallel to one another in these dimers but their average ring distance is ca. 
3.5 Å. The crystal structure bears a resemblance to the racemic equivalent (R,S)-
PSA·2(3,4LUT) with the common understanding that in this structure all PSA molecules are 
in the S-configuration (Figure 3.8c). 
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Figure 3.8 The ASU of 2(S-PSA)·4(3,4LUT) with hydrogen bonds and labelled contact atoms (a). The symmetry independent 
base-acid-base (BAB) units interact via hydrogen bonds and 𝜋-interactions between the 3,4LUT molecules (b), colouring 
based on symmetry equivalence). The packing of the crystal mimics the racemic structure (c). 
 
3.2.6 (R,S)-Phenylsuccinic acid 3,5-lutidine co-crystal salt: [(R,S)PSA2-]2[3,5LUT+]·2(R,S)-
PSA 
 
(R,S)-PSA crystallised from the solvent 3,5LUT in the centrosymmetric P21/c (No. 14) space 
group with three molecules of PSA and two molecules of 3,5LUT in the ASU (Figure 3.9a), 
dubbed as a pentamer. All three PSA molecules have linear succinic acid backbones but they 
differ in their protonation states. One of the PSA is deprotonated on both ends, and thus the 
hydrogen bonded 3,5LUT molecules are protonated to form the charged BAB unit              
[(R,S)-PSA2-]2[3,5LUT+]. In these units, the PSA is disordered in two positions, with the main 
disorder occupying 70% of the positions. (The minor disorder is shown with wireframe 
representation on Figure 3.9a. In the following figures the atoms of the minor disorder are 
omitted for clarity.) The other two neutral PSA molecules hydrogen bond between two 
neighbouring BAB units (shown yellow and grey on Figure 3.9b). The data collection and 
refinement details as well as hydrogen bonds for [(R,S)-PSA2-]2[3,5LUT+]·2(R,S)-PSA are listed 
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in tables 3.6 and 3.7. The protonation states of the molecules were established based on 
evaluating the C-O bond lengths and also locating the hydrogen atoms in the electron density 
map. The C-O bond lengths for the C=O groups were found in the region of 1.17-1.20 Å, while 
they were found around 1.3 Å for the C-O groups. For the deprotonated carboxylate groups 
these values were between 1.22-1.26 Å. Subsequently, the protonation of the lutidines were 
proven by locating the hydrogen atoms from the aromatic nitrogen atoms at a distance of 0.92 
Å. Therefore, this crystal can be described as a co-crystal salt based on Grothe et al.4  
The hydrogen bonded pentamers, i.e. the ionic BAB units and the linking neutral PSA 
molecules, form tapes and these interact with neighbouring counterparts via weak aromatic 
interactions formed between the lutidinium ions (Figure 3.9c). They are in offset positions with 
the ring distance of ca. 3.5 Å and the plane of the rings are in ca. 2° incline (inset of Figure 
3.9c). 
 
Figure 3.9 The ASU of [(R,S)-PSA2-]2[3,5LUT+]·2(R,S)-PSA with hydrogen bonds and labelled contact atoms (a). The 
hydrogen bonds between the neighbouring supramolecular units (equivalent of ASU) (b, colouring based on symmetry 
equivalence). The hydrogen bonded columns running down [100] direction interact via weak aromatic interactions formed 
between the lutidinium cations (inset, c). 
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3.2.7 (S)-Phenylsuccinic acid 3,5-lutidine co-crystal salt: 2[(S)-PSA2-]4[3,5LUT+]·4 (S)-PSA 
 
(S)-PSA crystallised from the solvent 3,5LUT in the non-centrosymmetric P1 (No. 1) space 
group with six molecules of PSA and four molecules of 3,5LUT in the ASU. This ASU is 
mimicking the ASU of the racemic crystal, [(R,S)-PSA2-]2[3,5LUT+]·2(R,S)-PSA, but 
contains two pentamers (Figure 3.10a). Basically, this ASU is double that of the ASU seen in 
the racemic crystal. The possibility of disordered ionic PSAs was investigated but the 
refinement was unstable after the atoms were split. (See details in the relevant checkCIF 
report.). Crystal data, refinement details and hydrogen bonds of 2[(S)-PSA2-]4[3,5LUT+]·4(S)-
PSA are summarised in Tables 3.6 and 3.7. The protonation states of the molecules, and 
subsequently the pentamers, were established by following the method explained in the case of 
the [(R,S)-PSA2-]2[3,5LUT+]·2(R,S)-PSA crystal and found to be identical to it. The overall 
arrangement of the molecules in the two pentamers in the ASU are similar but not identical. 
The difference between the pentamers is shown in Figure 3.10b, where the deprotonated PSA 
ions are overlaid (central blue and yellow molecules) and their hydrogen bonded neighbours 
are presented with the same colour as the central PSA. It is clearly seen that the molecular fit 
of the central PSA ions is good and the obvious difference is noted between the positions of 
the hydrogen bonded lutidinium ions and also hydrogen bonded neutral PSA molecules. The 
overall packing of the chiral crystal is very similar to the racemic crystal; both have a layered 
structure where the hydrogen bonded units interact with neighbouring units via the weak 
interactions between the lutidinium ions. In the case of 2[(S)-PSA2-]4[3,5LUT+]·4(S)-PSA, the 
offset is more prominent between the aromatic rings. This offset 𝜋-stacking arrangement causes 
the subsequent layers to be shifted in the structure of 2[(S)-PSA2-]4[3,5LUT+]·4(S)-PSA. The 
overlap of the crystal structures of [(R,S)-PSA2-]2[3,5LUT+]·2(R,S)-PSA (black, Figure 3.10c) 
and 2[(S)-PSA2-]4[3,5LUT+]·4(S)-PSA (red, Figure 3.10c) shows good agreement in the 
packing when compared layer by layer, but also shows the molecular shift between the 
subsequent layers in the chiral structure. 
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Figure 3.10 The ASU of 2[(S)-PSA2-]4[3,5LUT+]·4(S)-PSA (half of the unit is coloured with yellow for clarity) (a). The 
overlap of the two pentamer subunits of the ASU (b). Overlap of the crystal structures of [(R,S)-PSA2-]2[3,5LUT+]·2(R,S)-
PSA (black) and 2[(S)-PSA2-]4[3,5LUT+]·4 (S)-PSA (red) shows good agreement in the packing when compared layer by 
layer but also shows the molecular shift between the subsequent layers (c). 
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3.3 Multicomponent crystal formation of phenylsuccinic acid with pyrazine 
carboxamide 
 
Both (R,S)-PSA and (S)-PSA were exposed to pyrazineamide (pyrazine carboxamide, PCA), 
a first-line antituberculous drug, but only the racemic acid was co-crystallised successfully with 
PCA.  
 
3.3.1 (R,S)-Phenylsuccinic acid pyrazine carboxamide co-crystal: (R,S)-PSA·PCA 
 
Co-crystallisation of racemic PSA and PCA in a 1:1 ratio resulted a co-crystal with the same 
stoichiometry. The compound crystallised in the centrosymmetric 𝑃1̅ (No. 2) space group and 
contains one molecule of PSA and one molecule of PCA in the ASU (Figure 3.11a). The 
succinic acid backbone of the PSA is bent and there was no proton transfer observed between 
the acid and the drug coformer. The PSA forms (1) an acid-amide heterodimer with the PCA 
that can be described with 𝑅2
2(8) graph set (Figure 3.11a) and (2) an acid-acid homodimer via 
O11-H11···O10 and its symmetry generated counterpart. (This interaction can be described 
with the same graph set notation as the acid-amide heterodimer.) Based on intermolecular 
potential calculations5,6 the strongest interaction in the crystal is the acid-acid homodimer          
(-41.8 kJ mol-1) and the second strongest interaction is the acid-amide heterodimer                         
(-39.0 kJ mol-1). Therefore, it may be concluded that the supramolecular building unit of the 
crystal is the PCA-PSA-PSA-PCA tetramer (highlighted on Figure 3.11b with yellow). The 
tetramers interact with neighbouring units via the PCA moieties forming C20-H20···N22 and 
C23-H23···N19 hydrogen bonds (Figure 3.11b) and also weak hydrogen bonds are formed 
between the adjacent coplanar acid dimers (C6-H6···O10 and C7-H7···O11, Figure 3.11c). 
The crystal packing has a layered nature in the direction of [001] with alternating PSA and 
PCA layers (Figure 3.11d). The crystallographic details and hydrogen bonds for (R,S)-PSA·PCA 
are summarised in Tables 3.8 and 3.9. 
Chapter III: Crystal structures 
 
 
      
51 
 
 
Figure 3.11 The ASU of (R,S)-PSA·PCA with labelled heavy atoms and the acid-amide dimer formation between PCA and 
PSA (a). Hydrogen bonds between the adjacent PCA molecules and the acid dimer formation between neighbouring PSA 
molecules (b). Hydrogen bonds between neighbouring acid dimers (c). Layered nature of the structure (PCA molecules with 
blue, PSA molecules with green colouring) (d). 
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Table 3.8 Crystal data for (R,S)-PSA•PCA. 
Crystal data 
Compounds (R,S)-PSA•PCA 
Molecular formula  C15H15N3O5 
Formula weight (g.mol-1) 317.30 
Crystal system Triclinic 
Space group P1̅(2) 
a (Å) 5.7726(12) 
b (Å) 7.9815(16) 
c (Å) 16.594(3) 
α (°)  99.36(3) 
β (°) 99.28(3) 
γ (°) 97.44(3) 
V (Å) 734.9(3) 
Z 2 
ρcalc/ g.cm-3 1.434 
μ (MoKα) / mm-1 0.110 
F (000) 332 
Crystal size (mm) 0.040 × 0.220 × 0.900 
Temperature (K) 173(2) 
Radiation [Å] MoKα (0.71073 Å) 
Theta min-max [°] 1.266, 28.353 
Dataset -7:7, -10:10, -22:22 
Final R indices [I > 2.0 (I)] R1 = 0.0403, wR2 = 0.0898 
R indices (all data) R1 = 0.0553, wR2 = 0.0971 
Tot., uniq.data, R (int) 19165, 2858, 0.0416 
Nref, Npar 3666, 224 
S 1.040 
Max. ans av. Shift/error 0.001, 0.000 
Min. and max. resd. Dens (Å3) -0.210, 0.274 
 
Table 3.9 Hydrogen bonds in (R,S)-PSA•PCA. 
D-H•••A d(D-H) (Å) d(H•••A) (Å) d(D•••A) (Å) D-H•••A (°) Symmetry operator 
N17-H17A•••O13 0.89 2.08 2.949 163.8  
O14-H14•••O15 0.93 1.70 2.619 168.3  
O11-H11•••O10 0.91 1.74 2.653 176.0 -x+1, -y+2, -z+1 
C20-H20•••N22 0.95 2.57 3.418 149.4 x+1, y, z 
C23-H23•••N19 0.95 2.57 3.419 148.8 x-1, y, z 
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4.1 Conformation analysis of the phenylsuccinic acid moiety 
The PSA moiety showed a great variety of different conformations in the MCCs. To describe 
the conformations of the PSA, the following three torsion angles were considered: τ1 (Carom-
C-C-O), τ2 (Carom-C-C-C) and τ3 (C-C-C-O) represented in Figure 4.1. In order to assess the 
distinctive conformations, a comparison was made by listing the torsion angles of PSA in each 
of the crystal structures in Table 4.1. The two typical conformations of PSA are based on the 
position of the succinic acid backbone and can be describe as ‘linear’ or ‘bent’. These were 
mentioned in the related structural descriptions because of their obviousness (see chapter 3). 
The independent rotation of the two carboxylic acid groups add an overtone to these basic 
conformations and creates a great variety of conformations of the PSA presented in the MCCs. 
The visual representation of this complex behaviour is shown in Table 4 (fourth column) by 
colouring the common aromatic rings white and positioning them to the back of the figure. The 
snapshots of the molecular conformations were taken looking down the C-Carom bond, linking 
the aromatic ring and the backbone. The values of τ1 varied from -64.15° to -175.88°, while τ2 
variation was from -70.57° to 176.14° and τ3, with the largest variation, ranged from -160.12° 
to 164.75°.  
A recent study by Thompson and Day explained that molecules with large conformational 
flexibility often adopt high energy conformers when crystallising and compensate the 
energetically unfavoured conformation with the formation of inter- and intramolecular 
interactions.1 The cases of PSA MCCs presented here are a great representation of this kind of 
behaviour.  
 
 
Figure 4.1 Schematic representation of torsion angles of PSA. 
τ1 τ2
τ3
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Table 4.1 Torsion angles and molecular conformations of PSA in MCCs 
 
Crystal 
 
𝛕𝟏(°) 
 
𝛕𝟐(°) 
 
𝛕𝟑(°) 
 
Conformation 
 
 
[(R,S)-PSA-][ANI+] 
 
 
-64.15 
 
 
81.82 
 
 
-130.86 
 
 
 
 
[(S)-PSA2-][2ANI+]·ANI 
 
 
-105.83 
 
 
56.68 
 
 
-160.12 
 
 
 
 
(R,S)-PSA·2PYR 
 
 
-85.26 
 
 
176.14 
 
 
-6.65 
 
 
 
 
(R,S)-PSA·2(4PIC) 
 
 
-98.46 
 
 
65.87 
 
 
-159.22 
 
 
 
 
 
(R,S)-PSA·2(2,4LUT) 
 
 
-93.00 
 
 
111.36 
 
 
-11.73 
 
 
 
 
(R,S)-PSA·2(3,4LUT) 
 
 
-73.40 
 
 
169.02 
 
 
-6.36 
 
 
 
 
2(S-PSA)·4(3,4LUT) 
 
 
-113.11 
 
 
165.80 
 
 
-59.68 
 
 
  
 
-75.46 
 
 
171.77 
 
 
-10.97 
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Table 4.1 Torsion angles and molecular conformations of PSA in MCCs (cont.) 
Crystal 𝛕𝟏(°) 𝛕𝟐(°) 𝛕𝟑(°) Conformation 
 
 
[(R,S)-PSA2-]2[3,5LUT+]·2(R,S)-PSA 
 
 
-99.27 
 
 
-49.03 
 
 
-42.52 
 
 
  
 
-93.93 
 
 
60.12 
 
 
-138.99 
 
 
  
 
-71.72 
 
 
-70.57 
 
 
-31.28 
 
 
 
 
2[(S)-PSA2-]4[3,5LUT+]·4 (S)-PSA 
 
 
-78.14 
 
 
70.06 
 
 
-140.60 
 
 
  
 
-117.66 
 
 
76.08 
 
 
164.75 
 
 
  
 
-71.37 
 
 
46.24 
 
 
-130.48 
 
 
  
 
-175.88 
 
 
47.43 
 
 
-117.61 
 
 
  
 
-76.84 
 
 
61.30 
 
 
-140.35 
 
 
  
 
-127.54 
 
 
64.23 
 
 
154.65 
 
 
 
 
(R,S)-PSA·PCA 
 
 
-74.06 
 
 
173.47 
 
 
-18.10 
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4.2 Protonation state of PSA and the coformers in the multicomponent crystals 
The prediction of a crystal structure to be a salt or a co-crystal is possible by evaluating the 
difference in the pKa values of the acid-base pair that are included in the MCC. Therefore, the 
aqueous pKa values for the co-crystallised compounds, PSA and amines, were calculated with 
Marvin2 and are shown on Figure 4.2. The quantitative pKa rule by Cruz Cabeza
3 was used to 
calculate the ∆pKa values for the acid-base pairs (ΔpKa = pKa (base) – pKa (acid), Table 4.2). 
As it was emphasised by the author, the quantitative pKa rule was derived from “crystal 
structures in which one single proton was transferred, or the potential transfer of the most acidic 
proton of the acid to the most basic atom of the base, were considered (first ionisation constant 
only)”, therefore its application for the co-crystallisation of PSA, a diacid, should be evaluated 
with caution. The pKa values were calculated with both the more acidic (pKa = 4.07) and the 
less acidic (pKa = 5.67) carboxylic acid group of the PSA for clarity, but it was noted that only 
the values based on the first ionisation constants should be discussed (pKa 1). With the 
exception of the PCA, all coformers are liquids and were used as a ‘solvent’ during the co-
crystallisation experiments. This carries significance, hence the pKa value of a compound 
depends significantly on the solvent used to dissolve it. The co-crystal of PSA and PCA was 
obtained from methanol. However, the study of Cruz Cabeza on pKa did not cover the effect of 
different solvents, which acknowledgedly influence the values of the pKa.
4 The quantitative 
pKa rule states that co-crystals are expected to form if the pKa is below -1 (zone 1), salt 
formation is expected if the pKa is higher than 4 (zone 3) and, between these two boundaries 
lies the so called ‘salt-cocrystal continuum’ (zone 2)5 where, around pKa = 1, the formation 
of a salt or a co-crystal practically equal. The majority of the values, were found in zone 2, 
where the relative occurrence of ionised complexes increases linearly with increasing pKa 
values. The obtained values for pKa1 varied from 0.57 to 6.35 and spread across the pKa 
spectrum, with the majority lies in zone 2. It is unfortunate that none of the expectations that 
were based on the pKa values were successfully fulfilled by the formed crystals. The five 
types of crystal emerged from these crystallisations (a true salt, a salt solvate, a solvate, a co-
crystal and a co-crystal salt) emphasises further the complexity of zone 2 and this diversity 
points out again the importance of the recently published classification system for 
multicomponent crystals6. 
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Figure 4.2 pKa values of PSA and coformers 
 
Table 4.2 ∆pKa values for PSA and selected coformers 
Coformers Acid 𝚫pKa1* 𝚫pKa2* Expectation Outcome 
ANI (R,S)-PSA 0.57 -1.03 Co-crystal > salt True salt 
ANI (S)-PSA 0.57 -1.03 Co-crystal > salt Salt solvate 
PYR (R,S)-PSA 1.05 -0.55 Co-crystal ~ salt Solvate 
4PIC (R,S)-PSA 1.78 0.18 Co-crystal < salt Solvate 
2,4LUT (R,S)-PSA 2.51 0.91 Co-crystal < salt Solvate 
3,4LUT (R,S)-PSA 2.26 0.66 Co-crystal < salt Solvate 
3,4LUT (S)-PSA 2.26 0.66 Co-crystal < salt Solvate 
3,5LUT (R,S)-PSA 2.07 0.47 Co-crystal < salt Co-crystal salt 
3,5LUT (S)-PSA 2.07 0.47 Co-crystal < salt Co-crystal salt 
PCA (R,S)-PSA 6.35 4.75 Salt Co-crystal 
* ΔpKa = pKa (base) – pKa (acid)
4.07
5.67
4.64
5.12 5.85
13.06
-0.686.146.336.58
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4.3 Z parameters of the multicomponent crystals 
The discussed multicomponent crystal structures of PSA highlighted their structural 
complexity, but the complete description of the crystal structures cannot be finalised without 
the discussion of their full set of Z parameters. Due to the complexity of their nature it is crucial 
to define these parameters once again. The number of molecules in the entire unit cell is 
denoted as Z; the symbol Z’ is defined as the number of molecules in the unit cell divided by 
the group multiplicity; the parameter Z” is the sum of the components within the asymmetric 
unit, while Zr is the quantity of distinct kinds of chemical residues. It is important to note here, 
that enantiomers are not counted separately when Z’ and Zr values are calculated. Based on the 
definition of Zr, another problem arises too. 
Since co-crystals and salts are differentiated by the proton transfer from the acid to the base, it 
is logical to consider the neutral PSA and the deprotonated PSA as two different types of 
molecules. If this is the case, therefore, new Zr values can be allocated for some of the crystals 
and they are shown in brackets following the original values (Table 4.3). 
Steed and Steed stated that “There is no “driving force” toward Z′ = 1 or inherent preference 
for symmetry.” but they listed a series of scenarios when crystallisation may occur with Z’>1. 
Two of the cases are (1) when compounds crystallise with resolved chirality and therefore the 
possible symmetry operators are limited and (2) when strong directional intermolecular 
interactions are formed between the molecules. In the case of the PSA crystals discussed here, 
both of these listed situations are apparent. Excellent examples to represent the complexity of 
the problem are the racemic and enantiopure pairs of 3,4LUT and 3,5LUT crystals (Table 4.3). 
 
Table 4.3 Z Space groups and parameters for PSA MCCs 
Crystal Space group Z Z’ Z’’ Zr 
[(R,S)-PSA-][ANI+] Pn 2 1 2 2 
[(S)-PSA2-][2ANI+]·ANI P21 4 1 4 2 (3) 
(R,S)-PSA·2PYR P1̅ 2 1 3 2 
(R,S)-PSA·2(4PIC) P21/c 4 1 3 2 
(R,S)-PSA·2(2,4LUT) P21/c 4 1 3 2 
(R,S)-PSA·2(3,4LUT) P1̅ 2 1 3 2 
2(S)-PSA·4(3,4LUT) P1 2 2 6 2 
[(R,S)-PSA2-]2[3,5LUT+]·2(R,S)-PSA P21/c 4 1 5 2 (3) 
2[(S)-PSA2-]4[3,5LUT+]·4(S)-PSA P1 1 2 10 2 (3) 
(R,S)-PSA·PCA P1̅ 2 1 2 2 
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4.4 Structure-property relationships in PSA crystals 
Comparison of topology of inclusion compounds and how their physical chemical properties 
may be linked to this feature are in the centre of interest of the crystal engineering community.  
Ibragimov found correlation between the structures of host-guest complexes and their 
crystallisation temperatures and concluded that the crystallisation temperature increases with 
the decreasing host:guest ratio.7 It was also noted that the different topologies of the crystalline 
material can be described as (1) intercalate, (2) tubulate, or (3) cryptate, according to decreasing 
host:guest ratios (Fig. 4.3).8 To classify the PSA crystals according to this system, the bases 
were defined as the ‘guest’ and the PSA as the ‘host’. 
 
 
Figure 4.3 Change in topology with crystallisation temperature 
 
The bases (guest molecules) were removed from the structures and the volume of the created 
voids were calculated with the aid of Mercury (the probe size and the grid spacing were 1.2Å 
and 0.7Å, respectively). The graphical representation of the ‘empty’ host structures, the 
classification of the crystals, their calculated densities and the % void space are listed in Table 
4.4. Channels and layers were observed with the void percentage varying from 28.8% to 63.3%, 
while the densities are ranging from 1.221 to 1.341 g.cm-3.  
G GGG
G
G
G
G
Rising crystallisation
temperature
Low host/guest
ratio
High host/guest
ratio
Cryptate
Tubulate
Intercalate G
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Table 4.4 Densities, voids, solvent percentages for PSA MCCs 
 
Crystal 
 
Density 
 
%Base 
 
H:G ratio 
 
Type 
[(R,S)-PSA-][ANI+] 1.314 g.cm-3 36.5% 1:1  Tubulate 
 
 
 
[(S)-PSA2-][2ANI+]·ANI 1.221 g.cm-3 63.3% 1:3 Tubulate 
 
 
 
(R,S)-PSA·2PYR 1.341 g.cm-3 44.6% 1:2 Intercalate 
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Table 4.4 Densities, voids, solvent percentages for PSA MCCs (cont.) 
 
Crystal 
 
Density 
 
%Base 
 
H:G ratio 
 
Type 
(R,S)-PSA·2(4PIC) 1.272 g.cm-3 55.5% 1:2 Intercalate 
 
 
 
(R,S)-PSA·2(2,4LUT) 1.223 g.cm-3 54.6% 1:2 Intercalate 
 
 
 
(R,S)-PSA·2(3,4LUT) 1.255 g.cm-3 59.1% 1:2 Intercalate 
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Table 4.4 Densities, voids, solvent percentages for PSA MCCs (cont.) 
 
Crystal 
 
Density 
 
%Base 
 
H:G ratio 
 
Type 
2(S)-PSA·4(3,4LUT) 1.227 g.cm-3 58.1% 2:4 Intercalate 
 
 
 
[(R,S)-PSA2-] 
2[3,5LUT+]·2(R,S)-PSA 
1.298 g.cm-3 33.5% 2:3 Tubulate 
 
 
 
2[(S)-PSA2-] 
4[3,5LUT+]·4(S)-PSA 
1.296 g.cm-3 28.8% 4:6 Tubulate 
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Thermogravimetry analysis (TGA) and differential scanning calorimetry (DSC) were used to 
monitor the thermal behaviour of the PSA MCCs under thermal stress. The TGA results were 
used to obtain accurate PSA:base % ratios and DSC was applied to record accurate melting 
temperatures and melting enthalpies of the PSA crystals. The results for the pure PSA (racemic 
and S-enantiomer) and the PSA:base crystals are summarised in Table 4.5 while the TGA and 
DSC curves for the multicomponent crystals are presented in the Appendix. 
The TGA and DSC curves reveal congruent melting process for all the multicomponent 
crystals. Congruent melting occurs typically when a multicomponent compound melts and the 
composition of the melt (liquid) that forms is the same as the composition of the solid, i.e. there 
is no distinguishable step on the TGA curve that can be related undoubtedly to the release of 
the guest and thus subsequently, the DSC curve shows only one endotherm.9,10 The congruent 
melting observed in all of the MCC’s is due to the good solubility of the PSA in the bases used 
for the co-crystallisations. For example, the decomposition of the [(R,S)-PSA2-
]2[3,5LUT+]·2(R,S)-PSA and 2[(S)-PSA2-]4[3,5LUT+]·4(S)-PSA crystals produced a TGA 
curve with one step, thus the calculation of the % base ratio was impossible for the bulk 
material. For some of the crystals we were able to guess the step related to the release of the 
base by using the first derivative of the TGA curve but even in these crystals significant 
differences were found between the measured and the theoretical % mass losses that are 
ranging from 1.57% to 32.74%. 
Table 4.5 Thermoanalytical data for PSA MCCs 
 
Acid 
 
Coformer 
TGA DSC 
% DECOMPOSITION MELTING POINT 
Measured 
% 
Theoretical 
% 
Difference 
% 
H:G ratio Onset  
℃ 
Peak  
℃ 
∆H 
J/g 
∆T 
℃ TGA SCXRD 
(R,S)-PSA - n/a n/a n/a n/a n/a 170.15 171.97 146.37 n/a 
(S)-PSA - n/a n/a n/a n/a n/a 172.05 177.54 140.15 n/a 
PCA - n/a n/a n/a n/a n/a 189.09 191.34 194.54 n/a 
(R,S)-PSA ANI 30.84 32.41 -1.57 1:1 1:1 135.28 137.79 135.66 77.02 
(S)-PSA ANI 48.01 59.00 -10.99 1:2.4 1:3 61.00 63.55 108.30 78.92 
(R,S)-PSA PYR 34.01 44.89 -10.88 1:1.5 1:2 62.17 70.07 97.13 91.05 
(R,S)-PSA 4PIC 20.95 48.96 -28.01 1:0.9 1:2 65.72 69.76 92.76 77.02 
(R,S)-PSA 3,4LUT 30.61 59.07 -28.46 1:1 1:2 84.99 88.32 146.95 7.15 
(S)-PSA 3,4LUT 36.08 68.82 -32.74 2:2.1 2:4 55.46 63.46 80.25 9.05 
(R,S)-PSA 3,5LUT 97.32 62.34 n/a n/a 2:3 134.76 138.78 110.21 1.15 
(S)-PSA 3,5LUT 95.51 76.80 n/a n/a 4:6 97.12 103.19 71.79 3.05 
(R,S)-PSA PCA 97.21 55.91 n/a n/a 1:2 125.27 130.21 109.97 n/a 
*Thermoanalytical results for (R,S)-PSA‧2.4LUT were not performed due to lack of sample. 
*∆T = Tonset – Tboiling (base) 
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The melting endotherms recorded by DSC show that the starting materials (R,S-PSA and S-
PSA), have higher melting temperatures (Ton, R,S-PSA = 170.15 °C and Ton, S-PSA = 172.05 °C) 
compared to all the inclusion compounds, as well as the pharmaceutical co-crystal. It is also 
interesting to note that the chiral acid has higher melting point than the racemic counterpart. 
This is an interesting observation because, based on Wallach’s rule11, the melting point of a 
racemic crystal expected to be higher than its chiral counterpart, but PSA clearly does not fulfil 
this expectation.  
The melting temperatures of the MCCs are presented on a bar chart for clarity (Figure 4.4, for 
systematic comparison, the pharmaceutical co-crystal was excluded from the bar chart) and the 
bars are coloured according to the MCC classification system discussed in Chapter 1. The lower 
melting points relate to the solvates, while co-crystal salts or true salts have higher melting 
points. Comparison of the melting points of the racemic-chiral crystal pairs reveals that in all 
three cases (inclusion of ANI, 3,4LUT and 3,5LUT) the racemic crystals have significantly 
higher melting point than the chiral counterpart and, thus here Wallach’s rule is fulfilled. 
It is interesting to note that while the hydrogen bonding ability of the chiral and the racemic 
PSA is the same when exposed to aromatic amines, i.e. the same acid-base heterosynthon is 
expected to be formed, the crystal packing can differ significantly. It is understood that the 
crystal packing is a results of many more factors than the hydrogen bond formation between 
the acid and the base but it is intriguing how significant the effect of chirality can be on the 
packing and physical chemical properties of the multicomponent crystals.  
 
Figure 4.4 Colour coded bar chart of melting points of PSA MCCs 
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4.5 Occurrence of the 𝑹𝟐
𝟐(7) heterosynthon between carboxylic acid and aromatic amine 
moieties 
The formation of the 𝑅2
2(7) heterosynthon is an important crystal engineering tool. It is 
expected that this synthon forms when carboxylic acids hydrogen bond to aromatic amines. 
The formation of this synthon can happen when both the acid and the base stay neutral or the 
same graph set descriptor may be used to describe the synthon if proton transfer happens 
between the moieties and two charged molecular ions are interacting (Figure 4.5). The PSA 
MCCs discussed here are good examples for the formation of the 𝑅2
2(7) heterosynthon of both 
types. To understand how common these motifs occur, with a special focus on its formation in 
chiral and racemic crystals too, a CSD analysis was carried out (Cambridge Structural 
Database, Nov 2018) with the aid of ConQuest (version 2.0.2, build 246535). General search 
filters were applied: 3D coordinates determined, R < 10%, no errors, non-polymeric structures, 
and only single crystal structures were included. Organics were analysed separately and also 
subsets were created that include both organics and organometallics for completeness. The 
results of the organics are discussed here, and the results that contain both organics and 
organometallics are presented in the Appendix.  
The 𝑅2
2(7) heterosynthon may be formed between (1) a carboxylic acid and a pyridine moiety 
or (2) a carboxylate group and a pyridinium cation (Figure 4.5). The neutral (typically found 
in co-crystals) and the charged (typically found in salts) arrangements were investigated 
separately to compare the possible differences on the occurrence of the motifs. The results of 
the search are presented in Fig. 4.6 and 4.7. 
 
 
Figure 4.5 The 𝑅2
2(7) heterosynthon formed in co-crystals and salts 
 
 
Co-crystal Salt
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The subset of carboxylic acid and pyridine moieties gave 2500 hits, out of which 710 (28.4%) 
present the 𝑅2
2(7)  heterosynthon only, and 40 hits (5.6%) crystallised in space groups that are 
allow the crystallisation of enantiopure compounds. The majority of the 710 hits crystallised 
in centrosymmetric space groups (623 hits, 87.7%). In case of hydrogen transfer, i.e. when the 
𝑅2
2(7) heterosynthon forms between carboxylate and pyridinium moieties, the outcome of the 
analysis is similar. The subset of carboxylate and pyridinium moieties gave 1025 hits, out of 
which 256 (24.9%) present the 𝑅2
2(7) heterosynthon. 24 hits (9.37%) represents structures that 
crystallised in space groups that allow enantiopure compounds. The majority of the 256 hits 
crystallised in centrosymmetric space groups (217, 84.7%). It is interesting to note, that crystals 
with ‘double motifs’, i.e. when both charged and non-charged 𝑅2
2(7) heterosynthons occur in 
the same crystal, are very rare. Only 9 hits of this kind were found in the CSD and all of them 
crystallised in centrosymmetric space groups. 
Four of the PSA MCCs presented in this work ((R,S)-PSA·2PYR, (R,S)-PSA·2(4PIC), (R,S)-
PSA·2(2,4LUT) and (R,S)-PSA·2(3,4LUT)) form neutral 𝑅2
2(7) heterosynthons and 
crystallised in centrosymmetric space groups. The 2(S)-PSA·4(3,4LUT) also forms the 𝑅2
2(7) 
heterosynthon but, obviously, crystallises in a non-centrosymmetric space group. Interestingly, 
the inclusion compounds [(R,S)-PSA2-]2[3,5LUT+]·2(R,S)-PSA and 2[(S)-PSA2-
]4[3,5LUT+]·4(S)-PSA did not form the ‘expected’ 𝑅2
2(7) heterosynthon but the hydrogen 
bonds are similar in nature in both the chiral and the enantiopure crystals. In the crystal of 
(R,S)-PSA‧PCA the acid-amide synthon was observed instead of the 𝑅2
2(7) heterosynthon.  
To summarise, the statistical analysis showed that the occurrence of the formation of the 𝑅2
2(7) 
heterosynthon when both carboxylic acid/carboxylate and pyridine/pyridinium moieties are 
presented in the same crystal structure is around 25-30%. The formation of this synthon is less 
possible in the case of crystallising enantiopure crystals because the limitations of the packing 
of chiral compounds adds an extra constraint to the crystallisation step. Recently it was shown 
that molecules with large conformational flexibility may adopt high energy conformers when 
crystallising and, to compensate the energetically unfavoured conformation additional inter- 
and intramolecular interactions are formed.1 This scenario is especially valid for the 
crystallisation of enantiopure compounds. In a reverse logic, it is equally possible, that 
molecules will ‘sacrifice’ strong intermolecular interactions in favour of close packing during 
crystallisation. 
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Figure 4.6 Occurrence of carboxylic acid and pyridine moieties, and their combination in the 
CSD 
 
 
Figure 4.7 Occurrence of carboxylate and pyridinium moieties, and their combination in the 
CSD 
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Chiral molecules are known to contrast in their physical and chemical properties relying upon 
whether they are available as the racemate or the pure enantiomer. Thus, the design and 
production of the chiral and racemic crystalline materials with desired properties remain a 
difficult task. The primary aim of this research was to design and synthesise a series of (i) 
multicomponent crystals of phenylsuccinic acid, which have limited options for auxiliary 
interactions with added conformational flexibility, while the co-crystallising compounds 
(primary and aromatic amines) were varied systematically; and (ii) a series of pharmaceutical 
multicomponent crystals using pyrazine carboxamide while the co-crystallising compound or 
coformer was phenylsuccinic acid. The acid was used in a racemic mixture form and in an 
optical active enantiomer (S form), for both model and pharmaceutical multicomponent 
crystals. The dicarboxylic acid was chosen to explore the formation of the O–H⋯N hydrogen 
bonding and the synthon arrangement in the inclusion compounds to enlighten the effect of 
chirality on the crystal packing, while the choice of the bases was due to the position and 
quantity of the methyl groups around the pyridine moiety. Eleven new crystalline materials 
were synthesised by combining phenylsuccinic acid (PSA, racemate or the S-enantiomer), with 
primary or aromatic amines (aniline, ANI, pyridine, PYR, 4-picoline, 4PIC, 2,4-lutidine. 
2,4LUT, 3,4-lutidine, 3,4LUT and 3,5-lutidine, 3,5LUT) and the drug pyrazinecarboxamide 
(PCA). The multicomponent crystals formed were examined by differential scanning 
calorimetry, thermogravimetric analysis, powder and single crystal X-ray diffraction and 
Fourier transform infrared spectroscopy for their complete characterisation. Ten out of the 
eleven novel crystal structures resulted in multicomponent crystals with the expected 
composition, i.e. both the acid and the base were included in the crystal. Co-crystallisation of 
(R,S)-PSA with tert-butylamine (tBa) under atmospheric conditions produced crystals with 
unexpected chemical composition. The amine reacted with the atmospheric CO2 and formed a 
carbonate salt [2tBa+][COO2-]. The successful co-crystallisations resulted in a variety of 
different crystal forms: five solvates ((R,S)-PSA·2PYR, (R,S)-PSA·2(4PIC), (R,S)-
PSA·2(2,4LUT), (R,S)-PSA·2(3,4LUT), 2(S)-PSA·4(3,4LUT), two co-crystal salts ([(R,S)-
PSA2-]2[3,5LUT+]·2(R,S)-PSA and 2[(S)-PSA2-]4[3,5LUT+]·4(S)-PSA), one salt ([(R,S)-
PSA-][ANI+]), one salt-solvate ([(S)-PSA2-][2ANI+]·ANI) and a co-crystal (R,S)-PSA·PCA) 
were identified. Grinding was successfully used to reproduce the multicomponent crystals 
obtained via slow evaporation method with the exception of [(S)-PSA2-][2ANI+]·ANI. The task 
to obtain chiral crystals was extremely challenging. Only three bases (ANI, 3,4LUT and 
3,5LUT) were successfully co-crystallised with (S)-phenylsuccinic acid. The phenylsuccinic 
acid showed great conformational variety and the acid:base ratios varied significantly in the 
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obtained crystals: 1:1 in the co-crystal, 1:2 in the solvates, 2:3 in the co-crystal salts, and 1:1 
and 1:3 in the salt and salt solvate, respectively. The analysis of the crystal packing (Z and 
related parameters, void analysis, etc.) highlighted the complexity of the packing of the 
multicomponent crystals and the significant differences between the racemic multicomponent 
crystals and their chiral counterparts.Values of Z’> 1 were observed exclusively in the chiral 
structures of 2(S)-PSA·4(3,4LUT) and 2[(S)-PSA2-]4[3,5LUT+]·4(S)-PSA). 
The thermoanalysis of the multicomponent crystals revealed congruent melting due to the good 
solubility of the acid in the base; the decomposition curve showed no mass loss that could be 
associated to the release of the solvent/base. The melting points of the crystals revealed that 
the enantiopure crystals had lower melting points than their racemic counterparts which agrees 
well with the common observation that enantiopure structures pack less efficiently, indicated 
by the relatively lower densities, and therefore are expected to be less stable under thermal 
stress. 
The acid-base heterosynthon, depicted as 𝑅2
2(7), was formed between the carboxylic acid and 
the pyridine moiety only in five of the multicomponent crystals: (R,S)-PSA·2PYR, (R,S)-
PSA·2(4PIC), (R,S)-PSA·2(2,4LUT), (R,S)-PSA·2(3,4LUT) and 2(S)-PSA·4(3,4LUT). 
Interestingly, in the co-crystal of (R,S)-PSA‧PCA the carboxylic acid formed hydrogen bonds 
via the amide functional group of the PCA instead of via the aromatic nitrogen atom. In [(R,S)-
PSA2-]2[3,5LUT+]·2(R,S)-PSA, 2[(S)-PSA2-]4[3,5LUT+]·4(S)-PSA, [(R,S)-PSA-] [ANI+] and 
[(S)-PSA2-][2ANI+] the expected acid-amine heterosynthon was not formed. The occurrence 
of the 𝑅2
2(7) synthon was investigated on a statistically more significant dataset with the aid of 
the Cambridge Structural Database and the analysis revealed that the heterosynthon is formed 
only in 25-30% of the cases. It was also concluded that formation of the 𝑅2
2(7) synthon is less 
expected when crystallising enantiopure compounds because the limitations of the packing of 
chiral compounds adds an extra constraint to the packing of the crystal. 
We believe that the results presented here are important contributions to the field of crystal 
engineering and the supramolecular chemistry of chiral vs racemic formulations and, generate 
potential interest in the field of pharmaceutical formulations in the future. 
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[2tBa+][COO2-] 
 
 
Figure A.1 DSC curve of [2tBa+][COO2-] and the starting material. 
 
 
Figure A.2 TG curve of [2tBa+][COO2-]. 
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Figure A.3 PXRD curve of [2tBa+][COO2-] and the starting material. 
 
 
Figure A.4 IR curve of [2tBa+][COO2-] and the starting material. 
5 10 15 20 25 30 35 40 45 50
2θ(°)
[2tBa+][COO2-] (GFSC)
[2tBa+][COO2-] (BULK)
(R,S)-PSA + TBA (GROUND)
(R,S)-PSA
2862
1689
1206
2979
1644
1354
400900140019002400290034003900
T
ra
n
sm
it
ta
n
ce
 (
%
)
Wavenumber (cm⁻¹)
(R,S)-PSA [2tBa+][COO2-]
Appendix 
 
 
77 
 
[(R,S)-PSA-][ANI+] 
 
Figure B.1 DSC curve of [(R,S)-PSA-][ANI+] and the starting material. 
 
 
Figure B.2 TG curve of [(R,S)-PSA-][ANI+] 
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Figure B.3 PXRD curve of [(R,S)-PSA-][ANI+] and the starting material. 
 
 
Figure B.4 IR curve of [(R,S)-PSA-][ANI+] and the starting material.  
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[(S)-PSA2-] [2ANI+]·ANI  
 
Figure C.1 DSC curve of [(S)-PSA2-] [2ANI+]·ANI and the starting material. 
 
 
Figure C.2 TG curve of [(S)-PSA2-] [2ANI+]·ANI. 
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Figure C.3 PXRD curve of [(S)-PSA2-] [2ANI+]·ANI and the starting material. 
 
 
Figure C.4 IR curve of [(S)-PSA2-] [2ANI+]·ANI and the starting material.  
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(R,S)-PSA·2PYR 
 
Figure D.1 DSC curve of (R,S)-PSA·2PYR and the starting material. 
 
 
Figure D.2 TG curve of (R,S)-PSA·2PYR. 
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Figure D.3 PXRD curve of (R,S)-PSA·2PYR and the starting material. 
 
 
Figure D.4 IR curve of (R,S)-PSA·2PYR and the starting material 
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(R,S)-PSA·2(4PIC) 
 
Figure E.1 DSC curve of (R,S)-PSA·2(4PIC)  and the starting material. 
 
 
Figure E.2 TG curve of (R,S)-PSA·2(4PIC). 
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Figure E.3 PXRD curve of (R,S)-PSA·2(4PIC) and the starting material. 
 
 
Figure E.4 IR curve of (R,S)-PSA·2(4PIC) and the starting material. 
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(R,S)-PSA·2(3,4LUT) 
 
Figure F.1 DSC curve of (R,S)-PSA·2(3,4LUT) and the starting material. 
 
 
 Figure F.2 TG curve of (R,S)-PSA·2(3,4LUT) 
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Figure F.3 PXRD curve of (R,S)-PSA·2(3,4LUT) and the starting material. 
 
 
Figure F.4 IR curve of (R,S)-PSA·2(3,4LUT) and the starting material. 
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2(S)-PSA·4(3,4LUT) 
 
Figure G.1 DSC curve of 2(S)-PSA·4(3,4LUT) and the starting material. 
 
 
Figure G.2 TG curve of 2(S)-PSA·4(3,4LUT) 
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Figure G.3 PXRD curve of 2(S)-PSA·4(3,4LUT) and the starting material. 
 
 
Figure G.4 IR curve of 2(S)-PSA·4(3,4LUT) and the starting material. 
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[(R,S)-PSA2-] 2[3,5LUT+]·2(R,S)-PSA 
 
Figure H.1 DSC curve of [(R,S)-PSA2-] 2[3,5LUT+]·2(R,S)-PSA and the starting material. 
 
 
Figure H.2 TG curve of [(R,S)-PSA2-] 2[3,5LUT+]·2(R,S)-PSA. 
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Figure H.3 PXRD curve of [(R,S)-PSA2-] 2[3,5LUT+]·2(R,S)-PSA and the starting material. 
 
 
Figure H.4 IR curve of [(R,S)-PSA2-] 2[3,5LUT+]·2(R,S)-PSA and the starting material. 
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2[(S)-PSA2-]4[3,5LUT+]·4(S)-PSA 
 
Figure I.1 DSC curve of 2[(S)-PSA2-]4[3,5LUT+]·4(S)-PSA and the starting material. 
 
 
Figure I.2 TG curve of 2[(S)-PSA2-]4[3,5LUT+]·4(S)-PSA 
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Figure I.3 PXRD curve of 2[(S)-PSA2-]4[3,5LUT+]·4(S)-PSA and the starting material. 
 
 
Figure I.4 IR curve of 2[(S)-PSA2-]4[3,5LUT+]·4(S)-PSA and the starting material. 
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(R,S)-PSA·PCA 
 
Figure J.1 DSC curve of (R,S)-PSA·PCA and the starting materials. 
 
 
Figure J.2 TG curve of (R,S)-PSA·PCA 
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Figure J.3 PXRD curve of (R,S)-PSA·PCA and the starting materials. 
 
 
Figure J.4 IR curve of (R,S)-PSA·PCA and the starting materials. 
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Figure K.1 Occurrence of carboxylic acid and pyridine moieties, and their combination in 
the CSD (Organic & Inorganic) 
 
 
Figure K.2 Occurrence of carboxylate and pyridinium moieties, and their combination in the 
CSD (Organic & Inorganic) 
